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With adherence to combined antiretroviral therapy (cART), HIV infection can be 
considered a controllable chronic condition, but quality of life issues remain. The 
preeminent of which, HIV-associated neurocognitive disorders (HAND), encompasses an 
array of neurological complications and has persisted despite cART implementation. The 
symptoms of HAND can be exacerbated by opiate use, a common comorbidity for people 
infected with HIV (PWH). While neurons are not infected by HIV, they incur sublethal 
damage, with γ-amino butyric acid- (GABA)ergic function being particularly vulnerable to 
viral and inflammatory factors released by infected/affected glia. This dissertation 
presents studies on novel organoid and dissociated primary human CNS models of 
HAND, the latter of which showed diminished levels of K+ - Cl- cotransporter 2 (KCC2), a 
neuronal transporter that maintains low intracellular Cl-, after exposure to HIV-1 and HIV 
proteins ± morphine. GABAAR-mediated hyperpolarization is predicated upon activity of 
KCC2 and functional examination of these neurons revealed decreased hyperpolarization 
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and disinhibition in response to GABAAR activation due KCC2 loss. Additionally, we 
identified the mechanisms through which HIV-1 mediates KCC2 reduction: the HIV 
protein, transactivator of transcription (Tat), through activation of N-methyl-D-aspartate 
receptor (NMDAR), and the HIV protein, glycoprotein 120 (gp120), through a novel 
mechanism involving CCR5 activation. We also found that morphine acts through the µ 
opioid receptor (MOR) to dysregulate KCC2. Pharmacological maintenance of KCC2 with 
the KCC2 enhancer, CLP257, rescued HIV, Tat, and morphine effects on KCC2 and 
GABAAR activity. 
Common neurological deficits in PWH include memory and motor dysfunction which are 
likely the manifestations of HIV-induced hippocampal and striatal degeneration. Thus, we 
expanded our in vitro results to the glial fibrillary acidic protein (GFAP)-driven, 
doxycycline(DOX)-inducible Tat-transgenic mouse model of HAND. No changes in KCC2 
in the hippocampus were seen, but we did find significant Tat-induced loss of KCC2 in 
the striatum which was associated with locomotor abnormalities in these mice. We also 
rescued phosphorylation of serine 940-KCC2 leading to increased KCC2 membrane 
localization and restoration of baseline motor activity with oral gavage of the prodrug of 
CLP257, CLP290. Overall, our in vitro and in vivo results demonstrate KCC2 as a 









Chapter 1: Introduction 
 
The human immunodeficiency virus (HIV) 
 
Worldwide, 37.9 million people are infected with HIV with 1.7 million new infections 
in 2018 (UNAIDS, 2019). HIV infects cells of the immune system and can lead to nadir T-
cell counts below 200, a point at which someone is classified as having acquired 
immunodeficiency syndrome (AIDS). Both HIV subtypes (HIV-1, -2) are members of the 
lentivirus genus within the retrovirus family. HIV-1 is more transmissible and more 
prevalent worldwide than HIV-2 and is the focus of this dissertation. Four strains of HIV-
1 have been identified: M, O, N, and P. The most prevalent is strain M, which consists of 
10 clades (A, B, C, D, F, G, H, J, K), and circulating recombinant forms with clade B being 
the most prevalent subtype in America, Europe, and Australia (Gilbert et al., 2007). 
 HIV was first found to be the virus that causes AIDS in 1983 (Gallo et al., 1983) 
and later found to be derived from simian immunodeficiency virus  (Gao et al., 1999, 
Bailes et al., 2003, Chen et al., 1997). Initial cases were found in vulnerable communities 
including homosexual men (Brennan and Durack, 1981), injection drug users (CDC, 
1982b), and hemophiliacs (CDC, 1982a), reflecting the modes of HIV transmission. HIV 
can be passed through venous injection or exposure of mucous membrane or damaged 
tissue to certain bodily fluids (blood, semen, rectal fluids, vaginal fluids, and breast milk) 
of someone infected with HIV. Thus, HIV is most commonly transmitted by sexual 
intercourse and needle sharing. Initial treatments for HIV-infection primarily consisted of 
prophylaxis against opportunistic infections that arose due to reduced immune 
competence (CDC, 1997, Moore and Chaisson, 1996). Combined antiretroviral therapy 
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(cART), became the recommended treatment for HIV/AIDS patients in 1997 and 
dramatically shifted the progression of HIV (Gulick et al., 1997, Hammer et al., 1997, 
Moore and Chaisson, 1999). The World Health Organization estimates that 62% of PWH 
now have access to cART, which involves the administration of three or more 
antiretrovirals (ARVs) simultaneously. ARVs are designed to interfere with each stage in 
the life cycle of HIV. Until 2015, it was recommended to begin HIV+ patients on a cART 
regimen after their cluster of differentiation (CD) 4 count dropped below 350 cells/mL, but 
this was revised to begin cART as early as possible (UNAIDS, 2016).  Implementation of 
cART dramatically reduced viral replication and the viral load in many patients’ plasma to 
undetectable levels (<50 RNA copies/mL) and reduced the mortality rate of HIV by 50 – 
80%  in the first ten years of use (Delaney, 2006). 
HIV structure and life cycle 
The HIV membrane is comprised of a lipid bilayer and proteins crucial for binding 
and fusion with host cells, namely, glycoprotein 120 (gp120) and glycoprotein 41 (gp41). 
The core of the HIV virion houses the viral genome, two single stranded RNA molecules, 
and the viral proteins reverse transcriptase (RT) and integrase (IN) (Briggs et al., 2006).  
Following mucosal invasion via interactions with dendritic cells (Turville et al., 2005, 
Turville et al., 2004), HIV-1 has six major steps in its life cycle and, thus, there are six 
major classes of ARVs: (1) binding/fusion (entry inhibitors), (2) reverse transcription 
(Nucleoside/tide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs)), (3) integration (integration inhibitors (INIs)), (4) 
transcription/translation, (5) budding, and (6) proteolysis/maturation (protease inhibitors 
(PIs)).  Viral entry is initiated with binding of the viral coat protein, gp120, to CD4, found 
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primarily on helper T cells and macrophages/monocytes. Bound gp120 induces a 
conformational change, exposing a binding site for either C-C chemokine receptor type 5 
(CCR5) or C-X-C chemokine receptor type 4 (CXCR4) co-receptors, introducing the 
different tropisms of HIV (Alkhatib et al., 1996, Deng et al., 1996, Feng et al., 1996, Trkola 
et al., 1996). CCR5-tropic strains (R5-tropic) are the predominant HIV-1 strains for active 
transmission and replication and preferentially bind CCR5 receptors found on 
macrophages, monocytes and T-cells (Roos et al., 1992, Zhu et al., 1993, Schweighardt 
et al., 2004) and are the most common type detected in the brain (Strizki et al., 1996, 
Cunningham et al., 1997, Gorry et al., 2001). Some variants may shift co-receptor 
preference to CXCR4 (X4-tropic variants) found on T-cells at later stages of infection (Ho 
et al., 2007, Tasca et al., 2008, Ribeiro et al., 2006). Engagement of the co-receptor leads 
to a conformational change in gp41, fusing the viral and host membranes to allow for the 
insertion of the viral core. Entry inhibitors (maraviroc (MVC) and efurvitide) block the 
actions of gp120/gp41 to prevent CD4/co-receptor binding and viral and host membrane 
fusion. MVC is a CCR5 antagonist; efuvirtide binds gp41 preventing membrane fusion. 
After membrane fusion, partial uncoating of the capsid proteins of the core occurs, 
providing RT access to host deoxyribonucleoside triphosphates (dNTPs) to initiate 
reverse transcription of viral RNA to cDNA, while forming the pre-integration complex 
which can pass through the intact nuclear envelope (Forshey et al., 2002). NRTIs and 
NNRTIs target reverse transcription to halt the virus life cycle. NRTIs are analogs of 
dNTPs that can enter the catalytic site of RT; NNRTIs are allosteric modulators of RT 
(Sarafianos et al., 1999, Huang et al., 1998). Both inhibit RT activity, preventing 
conversion of viral RNA to cDNA. Host enzymes complete integration by repairing the 
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single strand gaps resulting in the HIV provirus, which can remain latent indefinitely (Folks 
et al., 1986), which is a feature common to lentiviruses. Activation of immune cells by the 
transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) 
or nuclear factor of activated T-cells induce low level transcription of the integrated viral 
DNA from the U3 promoter located in the upstream long terminal repeat (LTR) (Nabel 
and Baltimore, 1987, Siekevitz et al., 1987, Duh et al., 1989, Kinoshita et al., 1998). 
Transactivator of transcription (Tat) and Rev are the first proteins transcribed and 
translated. Tat is necessary for efficient transcription of other viral proteins. Tat recruits 
the host cellular protein transcription elongation factor-b (p-TEFb) to viral transactivation 
response element (TAR) to enhance the activity of host RNA polymerase II (Tahirov et 
al., 2010, Barboric et al., 2001). Viral mRNAs are produced as numerous alternate splice 
forms.  Smaller viral mRNAs can be transported directly out of the nucleus, while larger 
species require Rev binding of Rev response element on the env protein to create a 
nuclear export sequence (Daugherty et al., 2010). Once in the cytoplasm, viral mRNAs 
are translated into immature polypeptides by host machinery. Viral proteins congregate 
on the cellular membrane and begin to bud off of the host cell (Briggs et al., 2009, Carlson 
et al., 2010).  Concurrent with or directly after budding, HIV-1 protease cleaves the 
immature polypeptides into mature proteins resulting in a mature infective virion (Pettit et 
al., 1994, de Marco et al., 2010). PIs do not affect the ability of HIV to replicate and escape 
host cells it has already infected, but do prevent affected virion from infecting new cells 
(Kohl et al., 1988). 
HIV-associated neurocognitive disorders 
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Snider et al. (Snider et al., 1983) found that neurological impairments accompany 
AIDS. Early investigations of this phenomenon discovered encephalopathy in many HIV 
patients, demonstrating that HIV can harm the CNS (Masliah et al., 1992, Shaw et al., 
1985). Neurological impairments can range from asymptomatic (ANI) to HIV-associated 
dementia (HAD), collectively termed HIV-associated neurocognitive disorders (HAND). 
Affected neurological domains from HIV damage can include verbal/language ability, 
attention/working memory, executive function, memory, speed of information processing, 
sensory perception, and motor skills (Antinori et al., 2007). ANI and mild neurocognitive 
impairment (MNI) are diagnosed as impairment in two cognitive domains with and without 
impairment to daily life activities, respectively. HAD requires marked impairment in two or 
more domains with significant daily functional impairment (Antinori et al., 2007, Saylor et 
al., 2016). While the introduction of cART has reduced the prevalence of HAD, ANI and 
MNI have increased with an overall prevalence of HAND remaining stable (Heaton et al., 
2010). While effective cART can reduce HIV to nondetectable levels in the periphery 
(Autran et al., 1997, Komanduri et al., 1998, Lederman et al., 1998), the brain can act as 
a reservoir of HIV, which may be implicated in the persistent neurological effects of HIV 
infection (Gelman et al., 2013). The introduction of cART has also shifted domains of 
neurocognitive impairment. Pre-cART era patients had a significantly higher percent of 
impairment in tasks related to motor skills, cognitive speed, and verbal fluency, whereas, 
cART era patients had a higher percent impairment in processing speed, memory, and 
executive functioning (Heaton et al., 2010, Maki et al., 2015, Rubin et al., 2017). These 
changes reflect a shift from subcortical and white matter disruption to cortical impairment 
from pre-cART to cART eras (Cysique et al., 2004). In a 2008 review, Anthony and Bell 
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(Anthony and Bell, 2008) posit that a shift in pathology has occurred from the basal 
ganglia to the hippocampus, entorhinal cortex, and temporal cortex, reflecting the 
neurocognitive findings of the clinical data. cART has had subtle/variable effects on 
HAND partially due to variable blood brain barrier (BBB) penetrance of the ARVs used. 
More effective penetrance may help dampen some aspects underlying HAND, but some 
studies have found that those on cART with higher BBB penetrance have worsened 
neurological impairment (Marra et al., 2009). This may be a result of direct ARV 
neurotoxicity, potentially contributing to the continuation of HAND and the shift in affected 
brain areas and symptomology noted. In vitro studies on ARVs have found that some 
induce dendritic beading at physiologically relevant concentrations (Robertson et al., 
2012) and can prevent microglial phagocytosis of amyloid β (Aβ) (Giunta et al., 2011) 
offering mechanisms by which certain ARVs may contribute to CNS pathology. Even with 
effective cART, the neurotoxic HIV protein Tat can be found in the cerebrospinal fluid 
(CSF) of PWH on cART and is correlated with worse performance in motor speed and 
information processing (Henderson et al., 2019). 
The predominant theory underlying HIV entry into the CNS, dubbed the Trojan 
Horse Theory, posits that HIV crosses the BBB early after infection via infiltrating 
monocytes/macrophages and, possibly T cells. Specifically, infected CD14+/CD16+ 
monocytes are highly vulnerable to infection and critical for viral seeding of the CNS 
(Fischer-Smith et al., 2001, Ellery et al., 2007). Additionally, they have increased 
transmigration across the BBB due to HIV-induced C-C chemokine receptor type 2 
(CCR2)  elevation and heightened sensitivity to chemokine C-C motif ligand 2 (CCL2) 
(Williams et al., 2013). After entry, monocytes establish residence and produce virus 
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within the brain, which then infects susceptible CNS cells. Productive infection occurs in 
perivascular macrophages and microglia. There is also strong evidence showing infection 
of astrocytes (with unproductive viral replication) (Eugenin et al., 2011, Wiley et al., 1986, 
Deiva et al., 2006), and neural progenitor cells (NPCs) (Balinang et al., 2017, Lawrence 
et al., 2004, Schwartz et al., 2007, Skowronska et al., 2018). While microglia and 
macrophages are widely accepted to actively replicate and release infective HIV, both 
infected astrocytes and microglia also release neurotoxic HIV proteins. Further, even 
uninfected microglia and astrocytes respond to viral insult by shifting towards a 
proinflammatory phenotype. While neurons themselves are not infected, they incur 
damage through viral and proinflammatory factors released by infected/activated glia 
resulting in reduced axodendritic complexity, hyperexcitability, and possibly excitotoxicity. 
This neuronal damage resulting in disrupted circuitry, is thought to underlie the symptoms 
associated with HAND (Masliah et al., 1997). 
The role of microglia and resident macrophages in HAND 
Microglia are the resident immune cells of the CNS and play an integral role in 
synaptic and dendritic maintenance and, thus, facilitate neuronal circuitry through 
phagocytosis of cellular debris and synapses. Expression of CD4 and CCR5 begets 
microglial susceptibility to R5-tropic strains of HIV-1 infection (Gelman et al., 1997, 
Epstein and Gendelman, 1993). Along with perivascular macrophages and monocyte 
derived macrophages microglia are the primary sites of active replication in the brain. 
Viral DNA can be found in all three cell types (Wiley et al., 1986, Koenig et al., 1986) even 
with effective cART (Ko et al., 2019) and are thought to be sites of viral reservoir in the 
CNS (Wallet et al., 2019). At basal conditions, microglia have  ramified morphology, 
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surveying synapses and extracellular matrix for debris, but microglia of the HIV-infected 
brain have a reactive, ameboid morphology (Everall et al., 2009). Pre-cART era, 
postmortem staining of human brain sections found increased interleukin-1 β (IL-1β) and 
tumor necrosis factor (TNF) in the cerebral cortex and white matter of HIV patients 
compared to controls. Microglial activation can be found even in patients receiving 
effective cART (Garvey et al., 2014). In addition to increased markers of reactive 
microglia/inflammation, HIV Tat-exposed microglia have reduced phagocytosis in vitro 
(Giunta et al., 2008) which may contribute to the accumulation of Aβ in the brains of cART 
era HIV patients, a hallmark of neurodegeneration and Alzheimer’s Disease (Green et al., 
2005).  
 Microglia are exposed to HIV proteins in vivo including, Tat, gp120, Vpr, and nef. 
In vitro studies have examined how these factors affect microglia and their 
cytokine/chemokine profile after exposure. Microglia respond to HIV-1 infection, and Tat 
or gp120 exposure with a proinflammatory phenotype releasing CCL2 , CCL4, CXCL10, 
interferon γ (IFNγ), C-X-C motif chemokine ligand type 8, IL-1β, TNF, CCL5, IL-6, and IL-
8 in vitro which contributes to neuroinflammation and neurotoxicity in the HIV-infected 
brain (D'Aversa et al., 2004, Chivero et al., 2017, Jin et al., 2012, Sheng et al., 2000, El-
Hage et al., 2015). Several of these factors are also upregulated in in vivo models of 
HAND including TNF and IL-1β (Chivero et al., 2017, Jin et al., 2012). Tat exposure can 
also induce glutamate release by microglia, directly contributing to hyperexcitability 
(Gupta et al., 2010). Overall, microglia are susceptible to HIV infection, serving as a 
reservoir of virus in the brain. They exhibit decreased phagocytic capacity, and release 
neurotoxic inflammatory mediators that are either directly neurotoxic, or that result in 
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secondary neurotoxic outcomes via the activation of astrocytes and other resident CNS 
cells. They are critical drivers of the neuronal dysfunction that underlies the symptoms 
associated with HAND. 
The role of astrocytes in HAND 
Astrocytes perform a myriad of functions including phagocytosis, 
cytokine/chemokine release, metabolic/trophic support to neurons, and synaptic cleft 
clearance. These functions become dysregulated as a result of viral and inflammatory 
insult. Some studies provided evidence that astrocytes can be infected by HIV, albeit, 
unproductively (Churchill et al., 2006). While astrocytes express no detectable CD4, 
evidence indicates that they can be infected by HIV in vivo (Tornatore et al., 1994, Ranki 
et al., 1995, Takahashi et al., 1996, An et al., 1999, Anderson et al., 2003, Churchill et 
al., 2009) and in vitro under specific conditions (Li et al., 2020). Lacking CD4, astrocytic 
infection requires an alternate route of viral integration or internalization. The generally 
accepted mechanism involves CD4-independent endocytosis (Chauhan et al., 2014, Hao 
and Lyman, 1999). A recently published study described in detail the mechanism 
underlying productive HIV infection in human fetal astrocytes (Li et al., 2020). Their 
proposed mechanism involves CD4-indpendent, CXCR4-dependent endocytosis of 
immature virion and escape of endolysosomal degradation to establish productive 
infection. Immature virions are vital to this proposed mechanism. Maturation of the HIV 
viral particle occurs soon after budding from the host cell, thus, an infected lymphocyte 
must be in close proximity to the astrocyte, which corresponds with earlier proposed 
mechanisms that require cell-to-cell contact (Nath et al., 1995, Li et al., 2015, Luo and 
He, 2015) and post mortem studies showing that infected astrocytes are primarily found 
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in close proximity to vasculature (whereby astrocytic end feet would be in close proximity 
to circulating, infected lymphocytes). While difficult to quantify, evidence from studies that 
combined immunohistochemistry for astrocytic and microglial markers, laser 
microdissection, and PCR demonstrated that as much as 19% of astrocytes contain HIV 
DNA and the frequency of astrocytic infection was correlated with severity of neurological 
complications (Churchill et al., 2009). There is still some dispute regarding the presence 
of astrocytic infection in vivo (Ko et al., 2019), but the small sample size in this study may 
suggest that astrocytic infection varies between PWH, and may be dependent on viral 
strains present and lymphocyte infiltration of the CNS. These variables exemplify some 
components of cellular and viral heterogeneity of HIV infection and disease progression 
which likely underlie the heterogeneity of HAND.  
Regardless of how much infection occurs in vivo, astrogliosis has been well 
documented in postmortem tissue of HIV-1-infected subjects (Vitkovic and da Cunha, 
1995, Desplats et al., 2013, Xing et al., 2009) and astrocytes show elevated release of 
proinflammatory cytokines/chemokines in response to HIV proteins in vitro. HIV-1 Tat and 
gp120 stimulate an inflammatory response and the release of IL1β, CCL2, IL6, TNFα, 
CCL5, and CCL2 (Wesselingh et al., 1997, Nottet et al., 1995, El-Hage et al., 2009, El-
Hage et al., 2005, Weiss et al., 1999). Astrocytes also release stromal cell-derived factor 
1 in response to IL1β released by HIV infected macrophages (Churchill et al., 2009). 
Astrocytes take up extracellular Tat (Ma and Nath, 1997) and infected astrocytes can 
release Tat and gp120 (Fan and He, 2016, Rahimian and He, 2016, Chauhan et al., 2003, 
Toggas et al., 1994). These factors, along with those released by microglia, contribute to 
neuroinflammation of the HIV-infected brain. 
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Beyond their immune roles, astrocytes participate in the tripartite synapse, clearing 
excess neurotransmitters and, in some cases, releasing neurotransmitters themselves to 
modulate neuronal plasticity (Nedergaard, 1994, Parpura et al., 1994, Araque et al., 1998, 
Wang et al., 2012a). Astrocytic excitatory amino acid transporter (EAAT) 1 and EAAT2 
are the primary sources of glutamate clearance in the brain (Bergles and Jahr, 1997, 
Schousboe et al., 1977, Gundersen et al., 1995). EAAT2 is decreased after exposure to 
HIV proteins in vitro (Wang et al., 2003, Pappas et al., 1998) as well as in postmortem 
brain tissue of HIV-1 infected subjects (Xing et al., 2009). Resultant excess glutamate is 
then available to bind Ca2+ permeable channels such as N-methyl-D-aspartate receptor 
(NMDAR) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) 
contributing to aberrant neuronal activation and, thus, neuronal hyperexcitability. 
 The extreme metabolic demands of neuronal activity beget their reliance on 
astrocytic support in the form of lactate via the astrocyte-neuronal lactate shuttle. Lactate 
derived from astrocytes is released into the extracellular matrix for neurons to uptake to 
allow neuronal adenosine triphosphate (ATP) generation needed for synaptic 
transmission while bypassing the glycolytic pathway (Suzuki et al., 2011, Vilchez et al., 
2007). Tat induced rises in Ca2+ were found to increase mitochondrial Ca2+ uniporter Ca2+ 
uptake in astrocytes, resulting in decreased glycolysis and lactate transport to neurons 
(Natarajaseenivasan et al., 2018). Thus, Tat-induced astrocytic misallocation of energy 
substrates may deprive neurons of the metabolic support needed for proper neuronal 
activity. 
HIV-induced neuronal dysfunction 
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In addition to HIV/HIV protein-induced, glial-mediated neuroinflammation and 
neural homeostasis disruption, Tat and gp120 have direct neuronal targets. Tat has 
affinity for NMDAR (Haughey et al., 2001, Prendergast et al., 2002, Chandra et al., 2005, 
Self et al., 2004), and can activate AMPAR (Longordo et al., 2006, Fitting et al., 2014), 
voltage-gated L-type Ca2+ channels (Napier et al., 2014), and the transient receptor 
potential canonical channel (Peng et al., 2012), all of which lead to increased neuronal 
[Ca2+]i. In addition to dysregulating cell membrane Ca2+ channels, Tat induces release of 
Ca2+ through internal sources. Tat induction of inositol 1,4,5-triphosphate receptor and 
ryanodine receptor signaling pathways leads to increased [Ca2+]i from endoplasmic 
reticulum stores (Haughey et al., 1999, Perry et al., 2010). External influx and internal 
release disrupts Ca2+ homeostasis leading to excessive activation, metabolic disruption, 
and neuronal death in vitro (Kim et al., 2018, Nath et al., 1996, Brailou et al., 2008, Cheng 
et al., 1998, Norman et al., 2007, Zou et al., 2011). gp120 targets vary depending on 
tropism (CXCR4, CCR5, or dual (CXCR4- and CCR5-tropic)) and CXCR4 and CCR5 can 
both be found on subpopulations of neurons. Thus, CXCR4, CCR5, and dual-tropic gp120 
can also induce enhanced [Ca2+]i and neuronal death in vitro (Podhaizer et al., 2012, Kaul 
et al., 2007, Xu et al., 2011). While neuronal death is not often seen in vivo, the pathways 
initiated by Tat and gp120 can lead to loss of synaptodendritic complexity, 
hyperexcitability, and circuitry disruption found in these models of HAND and regulate, 
along with glial-mediated inflammation and metabolic disruption, neuropathology seen in 
PWH. 
The prevailing viewpoint on HIV-induced neuronal excitotoxicity and/or 
hyperexcitability has centered around excessive glutamate and neuronal [Ca2+]i, which 
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can result in a positive feedback loop, through increased [Ca2+]i stimulating glutamate 
release, which, in turn, activates [Ca2+]i permeable channels; a process that is further 
exacerbated by decreased astrocytic glutamate transport and increased microglial 
glutamate release. While increased excitation certainly tips the scale of neuronal 
excitatory-inhibitory balance, this only takes into account one side of the story. Increasing 
evidence of vulnerability of GABAergic markers and function has underscored the 
importance of loss of inhibition in HIV-induced excitatory-inhibitory imbalance. Human 
post-mortem brain gene expression array studies found downregulation of mRNA 
associated with GABAergic transmission in the neocortex and striatum of patients with 
HAND correlating with neurocognitive impairment (Gelman et al., 2012a, Buzhdygan et 
al., 2016). Corollaries to the changes in human gene expression have been found in DOX-
inducible, GFAP-driven Tat transgenic mice. Mice expressing the Tat transgene (Tat+) 
showed decreased inhibitory synaptic markers in the hippocampus associated with 
deficits in spatial memory compared to those lacking the Tat transgene (Tat-) mice (Fitting 
et al., 2013). These results were expanded upon to demonstrate selective loss of 
parvalbumin+, nitric oxide synthase+, neuropeptide Y- interneurons (Marks et al., 2016). 
Additionally, Tat+ striatal GABAergic neurons, particularly dopamine receptor D2 (D2R)-
expressing medium spiny neurons (MSNs) displayed reduced spine density and 
increased dendritic varicosities compared to their control counterparts (Fitting et al., 2010, 
Schier et al., 2017). Studies have also found disrupted GABA release and reduced 
amplitude and frequency of miniature induced post synaptic currents (mIPSC) from Tat 
exposure (Musante et al., 2010, Xu et al., 2016). These studies provide evidence of 
disinhibition through loss of GABAergic synapses and transmission after exposure to HIV 
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or HIV proteins and impetus to further study loss of inhibition in relation to the HIV-induced 
excitatory-inhibitory imbalance.  
Opiate use and its impact on HAND progression 
The United States is in the midst of an opioid epidemic with approximately 11 
million people reported to have misused opioids in 2017 (SAMHSA, 2017). Opiates act 
by mimicking endogenous opioid ligands, activating the µ-opioid receptor (MOR), and δ-
opioid receptor (DOR) and κ-opioid receptor (KOR) to a lesser extent. Due to their strong 
analgesic effects, opioids have been the primary source of prescription pain medication 
(National Academies of Sciences and Medicine, 2017). Activation of the classic reward 
pathway by opiates occurs through MOR activation and subsequent inactivation of 
GABAergic neurons resulting in disinhibition of ventral tegmental area (VTA) dopamine 
(DA)-ergic neurons and increased DA release in the nucleus accumbens (NAcc) 
(Johnson and North, 1992) which underlies the abuse liability of opiates.  
HIV infection and substance use disorders (SUD) are interlinked epidemics. 
Injection drug use (IDU) contributed to 20% of recorded HIV cases in 2016 (NIDA, 2019) 
and people who inject drugs are 22 times more likely to acquire HIV (UNAIDS, 2019). 
Illicit drug use is not the only route through which PWH are exposed to opiates. Recent 
studies found that 36% of PWH had chronic pain diagnoses and up to 50% of PWH were 
prescribed opiates (Chilunda et al., 2019, Denis et al., 2019). Drug use is associated with 
poor cART adherence and increased viral load in the CSF (Denis et al., 2019, Canan et 
al., 2018, King et al., 2012). Clinical data has been inconsistent in establishing a clear link 
between opiate use and the progression of HAND. One consistent confound being that 
most drug abusers use more than one substance, limiting conclusions that can be drawn 
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about the effects of opiates themselves. Despite this, some evidence has linked opiate 
use to worsened neurocognitive progression and higher rates of dementia (Chiesi et al., 
1996, Bell et al., 1998, Bell et al., 2002, Lucas et al., 2006, Byrd et al., 2011). Byrd and 
colleagues (Byrd et al., 2011) found an association between lifetime heroin use and poor 
recall association among PWH. Post mortem studies have also found that HIV 
encephalopathy indicators and markers of neuroinflammation were more prevalent in IDU 
than non-IDU HIV patients (Smith et al., 2014, Bell et al., 1998). Despite confounds, much 
of the literature associates higher prevalence and more rapid progression of 
neurocognitive impairment in HIV+ IDU than non-IDU which is in accordance with studies 
involving models of HAND and opiate exposure. Mechanisms underlying these changes 
involve convergence of cellular and molecular pathways that induce activation of viral 
reservoirs, enhanced cytokine and chemokine release, enhanced reductions of 
synaptodendritic complexity, increased glutamate release/decreased uptake, resulting in 
circuitry disruption and subsequent behavioral and cognitive deficits. 
Accumulating evidence showing reward deficits in PWH (Anderson et al., 2016, 
Plessis et al., 2015) suggests that the HIV-exposed CNS may have altered responses to 
drugs of abuse, possibly increasing the likelihood of drug seeking behavior and relapse 
in PWH. Imaging and postmortem studies have shown disrupted DAergic systems, such 
as reduced DA, dopamine transporters (DAT), D2R, and DA reuptake in the striatum 
(Chang et al., 2008, Wang et al., 2004, Kumar et al., 2009, Ferris et al., 2010), suggesting 
that HIV targeting of DAergic systems may underlie changes in reward processing. 
Several studies utilizing the DOX-inducible, GFAP-driven Tat-transgenic (Tat-transgenic) 
mice have identified potential neuronal and molecular targets underlying these clinical 
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effects. Tat exposure decreased DA levels (Kesby et al., 2016), impaired DAT function 
(Ferris et al., 2009a), decreased stimulated DA release (Ferris et al., 2009b), and 
decreased DA receptor expression in these mice (Kesby et al., 2016). Acute Tat exposure 
also increased the rewarding effects of drugs of abuse measured by behavioral 
assessment (Paris et al., 2014a, McLaughlin et al., 2014). Together, these studies 
suggest HIV infection of the CNS may increase the risk of substance abuse by altering 
the rewarding properties of drugs of abuse through impairment of DAergic circuitry. 
Opiates primarily exert their effects through activation of MOR, which can be found 
heterogeneously on neurons and glia. Opiates can increase HIV replication by decreasing 
IFN expression (Wang et al., 2012b) and susceptibility to infection by increasing CCR5 
expression (Guo et al., 2002, Li et al., 2003). Morphine, the primary metabolite of heroin, 
can reduce EAAT1 and 2 in vivo, directly contributing to excess glutamate, and has an 
additive effect with Tat to decrease glutamate buffering and increase microglial glutamate 
release, in vitro and exacerbate reactive oxygen species (ROS) release in a MOR 
dependent manner (Zou et al., 2011, Gupta et al., 2010, Turchan-Cholewo et al., 2009). 
Morphine enhanced Tat effects can result in exacerbated neuronal death in vitro through 
glial MOR activation (Zou et al., 2011) and may be dependent on the presence of glial 
CCR5 (Kim et al., 2018). Elevated neurotoxicity due to gp120-morphine co-exposure is 
dependent on gp120 tropism. Morphine significantly enhanced dual CXCR4-CCR5 tropic 
(MN) gp120-induced neurotoxicity while having no effects on CCR5 (ADA) or CXCR4 
(IIIB) toxicity (Podhaizer et al., 2012). Viral factors and morphine neurotoxic interactions 
may be mediated by glycogen synthase kinase 3β (GSK3β) signaling (Masvekar et al., 
2014, Masvekar et al., 2015) and may be glial-mediated (Zou et al., 2011).  
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Neuroinflammation in the HIV-opiate co-exposed brain may be sustained by 
astrocytic-microglial crosstalk.  Further, Tat and gp120-induced release of cytokines and 
chemokines are synergistically increased with morphine co-exposure (El-Hage et al., 
2005, El-Hage et al., 2006, El-Hage et al., 2008). Combined inflammatory effects of 
morphine and Tat emerge from convergence in elevated [Ca2+] and NFκB activation (El-
Hage et al., 2008).  Thus, morphine and HIV-induced inflammatory astrocytic response 
activates microglia to release proinflammatory factors resulting in a positive feedback loop 
creating a cycle of sustained neuroinflammation and hyperexcitability (Hauser et al., 
2012). 
KCC2 
 Preferential vulnerability of inhibitory neurotransmission to HIV-induced 
degeneration has been studied in regard to reduction of GABAergic machinery and 
synaptic markers (mRNA and protein) and frequency and amplitude of IPSCs. Other 
neurological disorders are increasingly finding GABAergic disruption through collapse of 
postsynaptic ionic gradients important for fast synaptic inhibition. Importantly, therapeutic 
efficacy has been demonstrated in targeting the transporters responsible for this ionic 
balance, such as K+- Cl- cotransporter-2 (KCC2). 
 Slc12a encodes 9 cation-Cl- transporters, including the central neuron specific, 
KCC2 (Hebert et al., 2004). KCC2 is a 12 membrane-spanning protein that can exist as 
monomers, dimers, trimers, or tetramers (Uvarov et al., 2009). Alternative splicing of the 
KCC2 gene can give rise to two isoforms that differ by 40 N-terminal amino acid residues, 
KCC2a and KCC2b (Uvarov et al., 2007). The longer isoform, KCC2a, is found more 
prominently in the neonatal brain stem and spinal cord while KCC2b is strongly 
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upregulated during development and is the predominant isoform in the adult brain (~90% 
of KCC2 expression in mature cortex) (Uvarov et al., 2007, Uvarov et al., 2009). Studies 
have not noted a difference in function between the isoforms. Both are central neuron-
specific (Uvarov et al., 2009) due to activity of the RE1-silencing transcription factor 
(REST) on the neuron restrictive silencer element upstream of the KCC2 promoter (Yeo 
et al., 2009). 
 KCC2 is an electroneutral secondary active transporter that utilizes the K+ gradient 
established by Na+-K+ adenosine 5’-triphosphate-(ATP)ase to extrude Cl-. This activity 
maintains low intracellular Cl- ([Cl-]i) driving the influx of this anion via the ligand gated, 
Cl- permeable GABAA and glycine receptors. Upon ligand binding, the inward rush of Cl- 
leads to hyperpolarization and inhibition of the postsynaptic neuron. KCC2 maintains low 
(<10 mM) [Cl-]i in mature mammalian neurons resulting in the reversal potential of 
GABAergic currents near resting membrane potential (Delpire and Staley, 2014). While 
setting the stage for postsynaptic hyperpolarization and inhibition through Cl- regulation, 
KCC2 has also been implicated in excitatory transmission. It has somatodendritic 
localization and clusters around dendritic spines (Gulyas et al., 2001, Gauvain et al., 
2011, Chamma et al., 2013) and through its interaction with cytoskeleton-associated 
protein 4.1 N KCC2 participates in stabilizing actin (Li et al., 2007) and is integral to 
dendritic spine formation and stability (Fiumelli et al., 2013), and, thus, is vital for 
glutamatergic plasticity. Taking into consideration its Cl- extrusion capacity to increase 
GABAergic inhibition and its localization to spines, KCC2 is fundamental to the excitatory-
inhibitory balance of neurons. 
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KCC2 is upregulated during development, due to brain derived neurotrophic factor 
(BDNF) activation of tropomyosin receptor kinase B (TrkB) on immature neurons, while a 
transporter with opposing Cl- displacement, Na+-K+-2Cl- cotransporter (NKCC1), is 
downregulated. This developmental shift was thought to result in the change of GABA 
from an excitatory to an inhibitory neurotransmitter (Rivera et al., 1999, Ben-Ari et al., 
1989, Chudotvorova et al., 2005), although some data suggested that conditions of these 
studies produced confounds that resulted in GABAergic excitation (Bregestovski and 
Bernard, 2012). In particular, the metabolic changes that occur to neurons during the 
slicing process for ex vivo slice electrophysiology may result in the accumulation of 
neuronal Cl- (Dzhala et al., 2012), thus, confounding experiments performed in these 
conditions. In vivo studies also demonstrated that application of GABAAR antagonists 
(gabazine and bicuculine) increased neuronal activity in rat pups (P3 - P5), suggesting 
inhibitory effects of GABAAR activation in the immature brain (Baram and Snead, 1990, 
Bernard and Axelrad, 1993). Some evidence from these studies has been refuted (Ben-
Ari et al., 2012). In direct contradiction to the studies above, experiments demonstrated 
that in P1 – 5 rats GABA does, in fact, excite immature neurons of the intact hippocampus 
in vitro (Valeeva et al., 2013) and that, in immature slice preparations, physiological 
concentrations of lactate or pyruvate do not alter the depolarizing effects of GABA, 
suggesting that depolarizing GABA is not an artifact of inadequate energy supplies (Tyzio 
et al., 2011). Further, blockade of NKCC1 with bumetanide in vivo during the early post-
natal period suppressed sharp waves in the hippocampus (Sipila et al., 2006), and 
attenuated electrographic seizures (Dzhala et al., 2005), suggesting depolarizing actions 
of GABA. These inconsistencies may be resolved through a suggested dual excitatory 
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and inhibitory role for GABA in the developing brain (Ben-Ari, 2014). This paradox may 
be due to shunting inhibition, whereby depolarizing GABA initially increases synchronous 
neuronal activation followed by reduced network activity by inhibiting depolarization 
above the GABA reversal potential, decreasing glutamate receptor currents (Khalilov et 
al., 1999). An attempt to finally resolve the role of GABA during development was made 
by Kirmse and colleagues (Kirmse et al., 2015), in which in vivo whole-cell voltage-clamp 
and 2-photon Ca2+ recordings of P3 - 5 mouse V1 neurons were made during puff 
application of GABA. Their voltage-clamp findings demonstrated that GABA is 
depolarizing in the majority of cells, but did not induce action potentials and, thus, lacked 
direct excitatory effects. In vivo Ca2+ recording revealed that application of GABA did not 
induce Ca2+ transients and that application of GABA agonist (benzodiazepine) and 
antagonist (gabazine) strongly inhibited and promoted spontaneous networks, 
respectively. Taken together, these data show that GABA is depolarizing, but inhibitory 
at the network level (likely through shunting inhibition) in the immature CNS (Kirmse et 
al., 2015). While there has been debate as to the exact postsynaptic effects of GABA in 
the developing CNS, it should be noted that a shift in neuronal expression pattern from 
NKCC1 dominant to KCC2 dominant has not been questioned, but rather the 
physiological consequences of this phenomenon. 
Membrane localization of KCC2 is largely post-translationally regulated in mature 
neurons. With an average membrane turnover rate of 20 – 30 minutes (Lee et al., 2010, 
Rivera et al., 2004), its trafficking, membrane stability, and degradation are tightly 
regulated by several phosphorylation sites (Come et al., 2019). The KCC2 N-terminal 
domain (NTD) was demonstrated to be required for membrane trafficking through a study 
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involving NTD deletion and the C-terminal domain (CTD) is involved in membrane stability 
and contains the majority of phosphorylation sites (Friedel et al., 2017)  . Phosphorylation 
of S932, T934, S937, S940 increase membrane stability while phosphorylation of T1009, 
T1007, T906, Y903, Y1087, decrease its stability and activity. Proteomic studies identified 
several other phosphorylation sites on KCC2, but whether they play a role in 
transportation and/or stability remains unknown (Cordshagen et al., 2018, Weber et al., 
2014). Phosphorylation and consequential changes in KCC2 activity are mediated by 
several upstream pathways. One well-studied pathway involves protein kinase C (PKC) 
and protein phosphatase 1 (PP1)-dependent phosphorylation and dephosphorylation of 
serine 940 (S940), respectively. NMDAR activation and subsequent [Ca2+]i increase leads 
to a molecular pathway involving PP1 dephosphorylation of S940 and its internalization, 
evidenced by KCC2 rescue via AP5 antagonism of NMDAR (Lee et al., 2011). In contrast, 
PKC phosphorylation of S940 increases its membrane stability and decreases clathrin-
induced internalization (Lee et al., 2007). Conversely, phosphorylation of Y903 and 
Y1087 result in loss of KCC2 activity via clathrin dependent internalization and lysosomal 
degradation (Lee et al., 2010). Interestingly, both excitatory and inhibitory 
neurotransmission differentially regulate KCC2 membrane stability and activity. 
Postsynaptic excitation by glutamate decreases KCC2 membrane stability through 
NMDAR-associated mechanisms discussed above. GABA was recently shown to be an 
upstream regulator of KCC2 as well. Post synaptic increase in Cl- reduced with-no-lysine 
1 (WNK1) activity and subsequent phosphorylation of T1007, increasing its stability 
(Heubl et al., 2017). Thus, NMDAR-mediated Ca2+-induced decrease in activity and 
GABAAR-mediated Cl--induced increase provides another mechanism by which neurons 
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can fine tune the balance of inhibition/excitation through KCC2 membrane stability within 
localized dendritic compartments. 
The link between KCC2 and neurological disorders has grown steadily over the 
last two decades. Loss of KCC2 activity was first linked to models of epilepsy (Rivera et 
al., 2002) and mutations in Slca12 were later found to underlie febrile seizures and 
generalized epilepsy in small cohorts of humans (Puskarjov et al., 2014, Kahle et al., 
2014). KCC2 loss precedes cyclothiazide-induced epileptiform activity, suggesting that it 
is the trigger setting the stage for seizures rather than a consequence of excessive 
NMDAR activation in these settings (Chen et al., 2017a). Hyperexcitability is a hallmark 
of many neuroinflammatory disorders. Evidence continues to accumulate linking KCC2 
loss and subsequent Cl- dysregulation as a mediator of hyperexcitability in several models 
of these diseases including Alzheimer’s disease (Chen et al., 2017b), traumatic brain 
injury (TBI) (Lizhnyak et al., 2019), Huntington’s (Dargaei et al., 2018), Rett syndrome 
(Tang et al., 2016), and neuropathic pain (Mapplebeck et al., 2019, Coull et al., 2005). A 
recent publication (Pisella et al., 2019) found that mice carrying a heterozygous KCC2 
mutation to reduce its Cl- extrusion capacity had ‘Autism-like’ phenotypes. Behaviors 
included abnormal ultrasonic vocalizations and social deficits which correlated with 
delayed GABAergic maturation.  
Opiate use and dependence are well known to dysregulate both spinal and striatal 
circuitry. Loss of KCC2 activity was found in lamina 1 neurons of the spinal dorsal horn 
disinhibiting spinal nociceptive output, after chronic morphine exposure inducing 
hyperalgesia (Ferrini et al., 2013, Ferrini et al., 2017). In contrast to immature neurons, 
TrkB activation downregulates KCC2 in mature neurons, which was shown to be the 
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mechanism here. Pharmacological maintenance of KCC2 was demonstrated to restore 
morphine’s analgesic effects in rats (Ferrini et al., 2017). During the development of 
morphine dependency, GABA switched from an inhibitory to excitatory signal in rats 
(Laviolette et al., 2004, Vargas-Perez et al., 2009). While not explicitly linked to KCC2, 
Cl- dysregulation is a likely mechanism underlying this switch and, thus, KCC2 is also 
likely dysregulated. 
Due to the increasing reports of KCC2 dysregulation in neurological diseases, 
Gagnon et al. (Gagnon et al., 2013) sought to design a compound that could maintain 
KCC2 activity. Through development of a novel KCC2 activity assay, they isolated 
CLP257, an arylmethylidine compound that restored Cl- extrusion in neurons treated with 
BDNF to reduce KCC2 activity and rescued KCC2 membrane expression. To enable in 
vivo study of pharmacological reintroduction of Cl- extrusion, a prodrug of CLP257, 
CLP290, was designed. CLP290 has a half-life of 5 h and is non-toxic with a maximum 
daily dose of 2,000 mg in rats (Gagnon et al., 2013). It was administered twice a day at 
100 mg/kg to rats to reverse morphine-induced hyperalgesia (Ferrini et al., 2017) and at 
50 mg/kg once a day to restore membrane expression and rescue rotarod performance 
after TBI (Lizhnyak et al., 2019). In mice, daily 35 mg/kg intraperitoneal injections of 
CLP290 restored stepping ability in spinal cord injured mice by restoring spinal cord 
inhibitory interneuron circuitry (Chen et al., 2018) and daily injections of 100 mg/kg to 
amyloid precursor protein knockouts rescued hippocampal inhibitory post synaptic 
current amplitude (Chen et al., 2017b). 
KCC2 activity and turnover is tightly regulated through the activity of REST, TrkB, 
kinase, and phosphatase activity mediated by numerous upstream pathways that play 
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important physiological roles in healthy CNS development and activity. These events 
include a developmental GABAergic switch, maintaining low [Cl-]i for postsynaptic 
hyperpolarization/inhibition, and maintenance of excitatory synapses and glutamatergic 
plasticity. These events can become dysregulated and contribute to hyperexcitability and 


















In vitro primary human CNS models 





In vitro models allow for the study of precise cellular and molecular pathways with 
control that may not be attainable using in vivo models. Rodent in vitro models have been 
instrumental in unravelling the mechanistic pathophysiology of many CNS disorders. 
Although, inherent drawbacks arise in the attempt to model human-specific diseases such 
as Alzheimer’s Disease, Parkinson’s Disease, and HIV-associated neurocognitive 
disorders (HAND) in nonhuman cells. Human induced pluripotent stem cells (hiPSCs) 
were first generated from reprogrammed human somatic skin cells (Takahashi et al., 
2007, Yu et al., 2007). hiPSCs have since advanced to the point of induction and 
differentiation of physiologically active human neurons with the capability of driving 
neuronal subset differentiation. These induced neurons (iNeurons) are critical to model 
human-specific CNS diseases. As with any model, there are inherent weaknesses found 
in iNeurons, including lost cytoarchitecture, reduced intercellular interactions, and artificial 
differentiation/development among others. Thus, for every study one must determine 
which model(s) can provide the most effective route towards answering the question at-
hand and must take into consideration the inherent strengths and weaknesses of each. 
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To attempt to restore aspects of cytoarchitecture and cellular diversity found in vivo 
while retaining the control provided by in vitro models, 3-dimensional (3D) organoid 
models have grown in favor. One early CNS organoid system, human brain aggregates 
(BrAgg), described by Pulliam and colleagues contain the major cellular subsets of the 
CNS in proportions similar to the human brain (40% neurons, 40% astrocytes, 15% 
oligodendrocytes, 5% microglia) (Pulliam et al., 1988, Pulliam et al., 1991, Pulliam et al., 
1998). Recent advances have shown the promise of such brain organoid development. 
Long-term culturing of hiPSC-derived organoids show major characteristics of the 
developing cortex including apical-basal polarity, interkinetic nuclear migration, neuronal 
migration and six cortical layers and brain region-specific organoids (Qian et al., 2018, 
Qian et al., 2016). 
  Here, we sought to develop and characterize translationally relevant primary 
human CNS models. We developed a differentiation protocol for a novel primary mixed 
astrocyte-neuron culture model (hNeuron) and further characterized BrAgg, initially 
described by Pulliam et al. (Pulliam et al., 1988) and demonstrate their utility as a model 
for HAND. The use of primary cells derived from human fetal CNS tissue, maintains 
natural cellular development until the point of pregnancy termination and BrAgg maintains 
critical intercellular interactions and provides stability for long-term culture experiments. 
Materials and Methods 
Primary hNPC dissociated culture.  
Human neural progenitor cells (hNPCs) were derived from human CNS tissue at 
15 - 17 weeks gestation (Advanced Biosciences Resources; Alameda, CA). Tissue was 
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passed through 120 µM mesh, centrifuged and washed with rinse media (DMEM 
supplemented with 1.5% glucose, 1% amphotericin B (Thermo Fisher), 50 ng/mL 
gentamycin, and 1% Pen/Strep) twice, and dissociated cells were plated on poly-L-lysine 
(10 µg/mL) and laminin (2 µg/mL) coated flasks. hNPCs were maintained in NPC media: 
DMEM F12 supplemented with 0.6% glucose, 10% B27 (without Vit A; Thermo Fisher 
Scientific), 20 ng/mL  fibroblast growth factor (FGF; R&D Systems, Minneapolis MN), 20 
ng/mL Epidermal growth factor (EGF; EMD Millipore, Billerica, MA), 10 ng/mL leukemia 
inhibitory factor (LIF; EMD Millipore, Billerica, MA), 1% Pen/Strep, 5 mM HEPES (N-2-
hydroxyethylpiperazine-N-3-ethane sulfonic acid; Thermo Fisher Scientific) with media 
changed every 3 or 4 days. 
Dissociated neuronal differentiation.  
Upon 80 - 90% confluency, hNPCs were detached using Accutase cell detachment 
solution (Millipore) and plated on poly-L-lysine (50 µg/mL) and laminin (100 µg/mL) 
coated 12-mm-diameter coverslips (immunostaining) or glass bottomed MatTek dishes 
(functional imaging) at 12,000 - 15,000 cells/coverslip in DMEM-F12 medium 
supplemented with 0.6% glucose, 10% B27 (without vitamin A; Thermo Fisher Scientific), 
1% Pen/Strep, 5 mM HEPES (Thermo Fisher Scientific), and 10 ng/mL brain derived 
neurotrophic factor (BDNF; Sigma). After 7 DIV, medium was exchanged gradually (50% 
on days 7 and 9) and then fully (100% every 72 - 96 h) to BrainPhysTM (STEMCELL 
Technologies Inc, Vancouver, BC, CAN) supplemented with SM1 (STEMCELL 
Technologies Inc). 
BrAgg culture.  
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BrAgg cultures were initiated and maintained using protocols established by 
Pulliam et al (Pulliam et al., 1988). Briefly, 15 – 17 wk human fetal CNS tissue (Advanced 
Biosciences Resources; Alameda CA) was passed through 120 µM mesh, centrifuged, 
and washed twice with rinse media. Cells were then transferred to SigmacoteTM (Sigma) 
coated 25 mL DeLong flasks at 30 million cells per flask containing 5 mL growth media 
(DMEM supplemented with 0.75% glucose, 50 ng/mL gentamycin (Thermo Fisher), 10% 
fetal bovine serum (FBS), and 1% Pen/Strep). After 48 h, BrAgg were transferred to 
sigmacote-coated 50 mL DeLong flasks containing 10 mL exchange media (DMEM with 
0.75% glucose, 50ng/mL gentamycin, 15% FBS, and 1% Pen/Strep). BrAgg were 
maintained rotating at 80 RPM in 10% CO2 and 37° C with 50% media change (exchange 
media) every 48 h. 
HIV-1 propagation and HIVsup preparation.  
HIV-1BaL was propagated using methods previously established (Balinang et al., 
2017). Briefly, isolated peripheral blood mononuclear cells (PBMCs) from peripheral 
blood Leuko Paks (ZenBio, Research Triangle Park, NC) were activated with 1 mg/mL 
phytohemagglutinin (PHA) for 48 h, then infected with HIV-1BaL (NIH AIDS Reagent 
Program) at 1 ng/mL [p24]. After 72 h, infection was assayed using p24 antigen ELISA 
kit (Advanced Bioscience, Rockville, MD) and supernatant harvested and frozen at −80° 
C for HIVsup experiments. HIVsup used in all BrAgg experiments was from the same source 
sample to reduce variability. 
Immunocytochemistry.  
hNeuron were fixed with 4% paraformaldehyde for 15 min after 21 DIV. Coverslips 
were then permeablilized with 0.1% Triton-X 100 in 0.1% BSA and blocked for 1 h at room 
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temperature in 0.1% BSA and 1% goat serum. Cellular markers were detected by 
incubating for 1 h with antibodies specific for microtubule-associated protein 2 (MAP2) 
(1:500; Millipore, Burlington, MA), glial fibrillary acidic protein (GFAP; 1:1000; Millipore), 
GAD67 (1:500; Abcam), glutaminase (1:500, Abcam), tyrosine hydroxylase (TH; 1:1000; 
Abcam), MOR (1:500; Antibodies Incorporated; Davis, CA), KCC2 (1:1000, Protein Tech), 
or NKCC1 (1:100; Abcam). AlexaFluor 488 and 594-conjugated secondary antibodies 
(1:1000, Thermo Fisher) were used and Hoechst 33342 (1:10000; Invitrogen) detected 
nuclei. 
BrAgg were fixed with 4% paraformaldehyde for 30 min, permeabilized for 30 min, 
and blocked for 1 h. BrAgg were incubated overnight with antibodies specific for MAP2, 
GFAP, Iba-1 (1:1000; Wako ), GAD67, and 2’3’-cyclic-nucleotide 3’-phosphodiesterase 
(CNPase; 1:500; Abcam) to determine cellular subsets present. AlexaFluor 488 and 594-
conjugatged secondary antibodies and Hoeschst33342 were used. 
Both hNeuron and BrAgg were visualized and images obtained with Zeiss LSM 
700 confocal module configured to an Axio Observer Z.1 and Zen 2010 software (Zeiss 
Inc.). 
BrAgg infection with HIV-1Ba-L.  
To determine infectivity of BrAgg, we incubated cultures with varying 
concentrations of purified HIV-1Ba-L or HIV-1Ba-L-infected PBMC supernatant (HIVsup) 
during culture initiation. BrAgg supernatants were collected and frozen with HALTTM 
Protease & Phosphatase inhibitor Cocktail (Thermo Fisher) to prevent protein 
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degradation at -80º C every 48 h. HIV-1 concentrations were then estimated using p24 
antigen ELISA kit (Advanced Bioscience, Rockville, MD). 
HIVsup Preparation. 
HIV-1BaL was propagated using methods previously established (Balinang et al., 
2017). Briefly, isolated PBMCs from peripheral blood Leuko Paks (ZenBio, Research 
Triangle Park, NC) were activated with 1 mg/mL PHA for 48 h, then infected with HIV-
1BaL (NIH AIDS Reagent Program) at 1 ng/mL p24. After 72 h, infection was assayed 
using p24 antigen ELISA kit (Advanced Bioscience, Rockville, MD) and supernatant 
harvested and frozen at −80° C for HIVsup experiments. HIVsup used in all experiments 
was from the same source sample to reduce variability.  
Statistics.  
Changes in BrAgg [p24] within subjects (across days) were assessed by repeated-
measures analysis of variance (ANOVA) in R. Bonferroni post hoc analysis corrected for 
multiple comparisons after comparisons of simple main effects. Effects were considered 
significant when p < 0.05. 
Results 
hNPC differentiation and hNeuron characterization.  
We developed a protocol to differentiate hNPCs into mature hNeurons. EGF, FGF, 
and LIF initially maintain hNPC pluripotency. These factors were replaced with BDNF to 
promote neuronal survival and differentiation for seven days. Next, cells were gradually 
transitioned to BrainPhys medium, which more accurately mimics in vivo physiological 
conditions, increases spontaneous and evoked action potentials, and increases 
33 
 
frequency and amplitude of spontaneous and induced inhibitory post synaptic potentials 
(IPSCs) compared to classic basal media (Bardy et al., 2015). After a total of 3 weeks in 
vitro, 53 ± 3.3% of cells are MAP2+/ GFAP- neurons and 44 ± 3.5% GFAP+ astrocytes 
(Fig. 2.1). Neurons were found to be primarily glutaminase+ (~75%), and glutamate 
decarboxylase+ (~25%), with few tyrosine hydroxylase+ (~1%) neurons (Fig. 2.2). Both 
neurons and glia present in these cultures were found to express MOR (Fig. 2.2). NKCC1 
is expressed on immature neurons and opposes KCC2 activity by increasing neuronal 
[Cl−]i. Its expression decreased to undetectable levels by 21 days in vitro (DIV), while 
KCC2 expression increased, as expected from studies on neuronal maturation (Schulte 
et al., 2018) (Fig. 2.1). These characteristics suggested that hNeurons had matured 
enough to hyperpolarize in response to GABAAR activation, as evident in experiments 
performed in Chapter 3.  
BrAgg characterization.  
BrAgg were fixed and stained for cellular markers from five to 29 DIV. We detected 
the presence of astrocytes (GFAP+), neurons (MAP2+/GFAP-), oligodendrocytes 
(CNPase+), and microglia (Iba1+) (Fig. 2.2). Neurons and astrocytes were present by 5 
DIV and make up a majority of the cellular subsets (~40% each) (Fig. 2.2). 
Oligodendrocytes and microglia make up the majority of the remaining cells present. 
Oligodendrocytes were detected at 21 DIV. Microglia were detected at 5 DIV (the earliest 
time point at which BrAgg were fixed and immunostained), but have distinct lineage from 
NPC derived neurons, astrocytes, and oligodendrocytes, appear in the human CNS by 5 
gestational weeks and, thus, are present in BrAgg from culture initiation (Bertrand et al., 
2005, Rezaie and Male, 1999). All microglia imaged have amoeboid morphology 
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suggesting a proinflammatory phenotype. The neurons present appear to be GABAergic, 
evidenced by detection of GAD67 on the majority of neurons visualized (Fig 2.2). 
HIV-1Ba-L infection of BrAgg. 
We sought to develop a model of HAND that more accurately mimics the 
cytodiversity and chronic infective and inflammatory environment of the HIV-infected brain 
while retaining the high levels of control and manipulation afforded by in vitro models. HIV 
is capable of infecting microglia and astrocytes, thus, we wanted to create a model 
reflecting this aspect of the disease. In order to achieve this goal, we determined if we 
could gain active HIV-1Ba-L infection of BrAgg. Challenges inherent to this process include 
determining the ideal paradigm (pure HIV-1Ba-L vs. HIVsup, concentration) to infect BrAgg 
and washing out potentially new infective virus with each media change. We exposed 
BrAgg to 0.5 – 2.5 ng of purified HIV-1BA-L or HIVsup (added to achieve a final concentration 
of 1 ng/mL [p24]). To tackle the issue of ‘lost’ virus at each media change (50% change 
every 48 h), we calculated the levels at which [p24] would be expected given day 1 
concentrations and simply divided by two for each consecutive media change ([p24exp]) 
and subsequently subtracted that from the observed [p24] of each sample ([p24obs]) . For 
example, if [p24] on Day 1 was 10 pg/mL, then by Day 9 (after media changes on days 
1, 3, 5, and 7) [p24exp] = 0.625 pg/mL. Thus, the adjusted [p24] ([p24adj]) = [p24obs] – 
[p24exp]. The resultant figure (Fig 2.4) displays this [p24adj] value. This is not an ideal 
model of infectivity, given the activity of proteases etc. that would further decrease p24 
concentrations, but quantifying these data in this way does allow for the quantification of 
‘new’ [p24], and, therefore, better represents the infectivity of BrAgg. Analysis with 
repeated measures ANOVA revealed a significant increase in [p24adj] within groups 
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exposed to 1.25 ng HIV-1Ba-L on days 9 and 21 compared to day 1 (p < 0.05; n = 4; Fig 
2.4), suggesting active infection of BrAgg by HIV-1Ba-L. 
Discussion 
The studies outlined here describe primary human CNS models involving the 
differentiation of human gestational CNS derived hNPCs. We demonstrated that hNeuron 
increase immunoreactivity for KCC2 while decreasing NKCC1 expression throughout our 
novel differentiation protocol. These features allow for the mechanistic study of human 
neuronal and GABAergic maturation and should be explored in future studies. hNeurons 
also show promise for the study of human specific disorders in which either of these 
proteins may become dysregulated resulting in disrupted GABAergic inhibition. We also 
characterized BrAgg and found that all major cellular subsets of the CNS are present and 
demonstrate its utility as a novel model for HAND in which there was active HIV-1 infection 
of CNS cells. 
Drawbacks are inherent to all models of neurodegenerative disorders and the 
models described here are not immune to certain pitfalls. Tissue samples acquired for 
these studies are tested for HIV infection prior to shipment, but not all potential confounds 
can be controlled for. We cannot determine reasons for pregnancy termination (whether 
medical necessity or otherwise), control for exogenous substance exposure (drugs of 
abuse and others), or obtain maternal or paternal genetic information. We also did not 
control for potential genetic abnormalities, nor did we determine if the tissue had been 
exposed to other viruses. Early gestational tissue may also be difficult to acquire 
depending on the everchanging legal landscape surrounding legal access to legitimate 
centers for termination procedures. Once acquired, this is less of a concern for the 
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dissociated cultures, for which, tissue from one source can be proliferated as hNPCs, 
frozen, and used for several passages, allowing for each sample to be used in several 
experiments. Due to the sheer number of cells necessary for one flask of BrAgg (30 million 
cells), it is not feasible to expand and freeze hNPC for use as BrAgg. Rather, for each 
BrAgg culture initiation, a separate sample source is required. The BrAgg studies here 
are limited by sample size. This particularly affects studies with higher variability, such as 
our assessment of infectivity, limiting conclusions from these results. A higher sample 
size may have resulted in significant changes in [p24adj] at levels other than 1.25 ng HIV-
1Ba-L. 
In this chapter, we described a novel primary human mixed astrocyte-neuron 
culture model containing both GABAergic and glutamatergic neuronal subsets with 
matured Cl- transporter expression. This dissociated model is particularly useful to 
elucidate mechanisms underlying neuronal disruption for human specific disorders. We 
also characterized BrAgg organoids which maintain components of the cyto-diversity and 
proportionality of cell types of the intact human CNS. Both show promise as translationally 

























Figure 2.1. Differentiation and characterization of hNeuron. hNPCs differentiate to 
~55% MAP2+/GFAP- (green) and 40% GFAP (red)+ by 14 DIV (A). Representative 
images from hNeuron cultures showing immunofluorescence of MAP2 and GFAP after 




























Figure 2.2. Extended hNPC Differentiation. Following our neuronal differentiation 
protocol, cells lose NKCC1 expression and gain KCC2 expression by 21 DIV (A). After 
21 DIV, immunoreactivity for glutaminase and GAD67 demonstrate both excitatory 
and inhibitory neuronal subsets were present, respectively (B). hNeuron express MOR 










Figure 2.3. BrAgg characterization. BrAgg contain neurons and astrocytes by 5 DIV, 
indicated by positive staining for MAP2 and GFAP, respectively (A). Most neurons 
present appear to be GABAergic due to high colocalization between MAP2+ and 
GAD67+ cells (B). A minority of cells are also CNPase+ or Iba1+ indicating the 
presence of oligodendrocytes and microglia, respectively (C, D). BrAgg can vary in 







Figure 2.4 Infection of BrAgg with HIV-1Ba-L. Exposure to 1.25 ng/mL [p24] purified 
HIV-1Ba-L (blue) results in a significant increase in [p24] adjusted for initial [p24] and 
media changes on days 9 and 21 compared to day 1 (*; p < 0.05; n = 4) ([p24adj]). No 





HIV and opiates dysregulate K+-Cl- cotransporter 2 (KCC2) to cause GABAergic 
dysfunction in primary human neurons and Tat-transgenic mice 




Approximately half of people infected with HIV (PWH) exhibit HIV-associated 
neuropathology (neuroHIV), even when receiving combined antiretroviral therapy. Opiate 
use is widespread in PWH and exacerbates neuroHIV. While neurons themselves are not 
infected, they incur sublethal damage and GABAergic disruption is selectively vulnerable 
to viral and inflammatory factors released by infected/affected glia. Here, we demonstrate 
diminished K+-Cl− cotransporter 2 (KCC2) levels in primary human neurons after 
exposure to HIV-1 or HIV-1 proteins ± morphine, resulting in disruption of GABAAR-
mediated hyperpolarization/inhibition. We found that the HIV proteins Tat (acting through 
NMDA receptors), and R5-tropic gp120 (acting via CCR5), and morphine (acting through 
µ-opioid receptors) induce KCC2 loss. We demonstrate that modifying KCC2 levels or 
function, or antagonizing NMDAR, CCR5 or MOR rescues KCC2 and GABAAR-mediated 
hyperpolarization/inhibition in HIV, Tat, or gp120 ± morphine-exposed neurons. Using an 
inducible, Tat-transgenic mouse neuroHIV model, we found that chronic exposure to Tat 
also reduces KCC2. Our results identify KCC2 as a novel therapeutic target for 




Close to 38 million people worldwide are infected with HIV, with 50,000 new 
diagnoses of HIV-1 infection per year in the US alone (UNAIDS, 2019). Up to 50% of 
those infected with HIV-1 have CNS complications including HIV-associated 
neurocognitive disorders (HAND) (Antinori et al., 2007, Heaton et al., 2010). It is widely 
accepted that neurons are not infected by HIV-1. Neurological deficits in patients 
receiving combined antiretroviral therapy (cART) are likely due to sublethal neuronal 
stress and injury induced by viral proteins released from infected cells and persistent 
neuroinflammation, resulting in hyperexcitability (Anthony et al., 2005, Everall et al., 2009, 
Nath and Steiner, 2014, Neuenburg et al., 2002). Exposure to HIV-1 transactivator of 
transcription (Tat) depolarizes neurons and leads to electrophysiological dysfunction and 
hyperexcitability, partly through interactions with N-methyl-D-aspartic acid (NMDA) and 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Philippon et 
al., 1994, Krogh et al., 2014). Another HIV-1 protein, gp120, binds co-receptors C-C 
chemokine receptor type 5 (CCR5) and/or C-X-C chemokine receptor type 4 (CXCR4) 
(Wang et al., 2003) (Kaul et al., 2007), leading to neurotoxic glial and inflammatory effects, 
as well as direct neurotoxicity. Opiate use is often comorbid with HIV-1 infection and has 
been implicated in increased severity of HAND (Byrd et al., 2011, Carrico, 2011, Bell et 
al., 2006, Smith et al., 2014). This comorbidity is highlighted by recent HIV-1 outbreaks 
in communities experiencing a surge in opiate abuse (Conrad C, 2015). In vivo and in 
vitro models of HAND demonstrate that morphine, the primary bioactive metabolite of 
heroin in the CNS, exacerbates HIV-1-induced neuropathogenesis primarily through the 
activation of the µ-opioid receptor (MOR) on glia, and subsequent modulation of 
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neuroinflammation and reduced glutamate buffering (Rodriguez et al., 2017, Bokhari et 
al., 2009, Zou et al., 2011). 
GABAergic neurons seem to be selectively vulnerable to damage by Tat and HIV-
1 infection in mouse models and post-mortem brain tissue from HIV-infected patients, 
highlighting disinhibition as a potential mechanism underlying hyperexcitability in the HIV-
infected brain (Marks et al., 2016, Fitting et al., 2013, Buzhdygan et al., 2016, Gelman et 
al., 2012a). The deficits appear to result from a loss of GABAergic markers (including 
GAD1, GAD2, and GJD2) rather than the death of GABAergic interneurons in autopsy 
samples from PWH (Buzhdygan et al., 2016). Importantly, deficits in GABAergic markers 
differed significantly among brain regions and linked to worse cognitive performance, but 
these markers were unaffected by a history of drug abuse and differed minimally when 
comparing pre- and post-cART autopsy samples (Buzhdygan et al., 2016). 
KCC2 extrudes Cl− to maintain a low intracellular Cl− concentration ([Cl−]i) in 
mature neurons (Blaesse et al., 2009). GABAA and glycine receptor-induced fast synaptic 
inhibition is predicated on the maintenance of low neuronal [Cl−]i provided by KCC2 
activity. While upregulation and subsequent increases in KCC2 activity have been 
extensively studied in development, loss of KCC2 activity and/or expression have more 
recently been noted in a number of neurological disorders including epilepsy (Kahle et 
al., 2014, Puskarjov et al., 2014, Silayeva et al., 2015), traumatic brain injury (Lizhnyak 
et al., 2019), schizophrenia (Hyde et al., 2011, Tao et al., 2012, Arion and Lewis, 2011), 
Rett syndrome (Tang et al., 2016), Huntington’s disease (Dargaei et al., 2018), and 
morphine-induced hyperalgesia (Ferrini et al., 2013, Ferrini et al., 2017). The KCC2 
activity enhancer, CLP257, and its prodrug, CLP290, have allowed manipulation of KCC2 
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activity and rescued deficits in KCC2-deficient states (Gagnon et al., 2013). While models 
of HAND have been shown to disrupt GABAergic functioning, loss of KCC2 activity has 
not yet been implicated in these deficits. 
In addition to working with individual HIV-1 proteins, we exposed primary human 
neurons (hNeurons), derived and matured from neural progenitors (hNPC), to 
supernatant from HIV-1 infected monocytes (HIVsup). This supernatant reflects the 
complexity of an infective milieu in that it contains multiple inflammatory/reactive factors 
and virions, as well as viral proteins. The genetically encoded voltage (GEVI) and Ca2+ 
indicators (GECI), Archon1  (Piatkevich et al., 2018) and GCaMP6f (Chen et al., 2013), 
respectively, were used to examine the functional outcomes of interactions between an 
HIV+ environment and morphine on hNeurons. Specifically, we used Archon1 and 
GCaMP6f to examine changes in GABAAR-mediated hyperpolarization and inhibition, 
respectively. Importantly, this optical approach permitted us to manipulate and test 
functional outcomes absent the biohazards inherent with invasive electrophysiological 
measurements in the presence of infective HIV. Assessment of electrophysiological 
activity by Archon1 is equivalent to patch-clamp recording of neuronal spiking and 
subthreshold millivolt scale activity (Piatkevich et al., 2018). We demonstrate that HIVsup 
and morphine target KCC2 in hNeurons, resulting in loss of GABAAR mediated 
hyperpolarization (measured by Archon1) and inhibition (measured by GCaMP6f). This 
suggests that dysregulation of KCC2 may play a role in circuit hyperexcitability in the HIV-
infected brain. Further, we identify Tat, acting via an NMDA receptor (NMDAR)-mediated 
mechanism, and gp120ADA, acting via a novel, CCR5-mediated mechanism, as viral 
proteins that can dysregulate KCC2 and GABAAR-mediated inhibition. We also examined 
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the effects of Tat exposure on KCC2 in an in vivo model of HAND and found significantly 
diminished KCC2 in the striatum of these animals. Our results suggest KCC2 and its 
upstream regulators as promising therapeutic targets to alleviate the symptoms of HAND 
± comorbid opiate use.  
Materials and Methods 
Primary hNPC culture.  
Human neural progenitor cells (hNPCs) were derived from human CNS tissue at 
15 - 17 weeks gestation (Advanced Biosciences Resources; Alameda, CA). Tissue was 
passed through 120 µM mesh, centrifuged and washed with medium twice, and 
dissociated cells were plated on poly-L-lysine (10 µg/mL) and laminin (2 µg/mL) coated 
flasks. hNPCs were maintained in NPC medium: DMEM F12 supplemented with 0.6% 
glucose, 10% B27 (without vitamin A; Thermo Fisher Scientific), 20 ng/mL fibroblast 
growth factor (FGF; R&D Systems, Minneapolis, MN), 20 ng/mL epidermal growth factor 
(EGF; EMD Millipore, Billerica, MA), 10 ng/mL leukemia inhibitory factor (LIF; EMD 
Millipore, Billerica, MA), 1% Pen/Strep, 5 mM HEPES (N-2-hydroxyethylpiperazine-N-3-
ethane sulfonic acid; Thermo Fisher Scientific) with medium changed every 3 - 4 days. 
Neuronal Differentiation.  
Upon 80 - 90% confluency, hNPCs were detached using Accutase cell detachment 
solution (Millipore) and plated on poly-L-lysine (50 µg/mL) and laminin (100 µg/mL) 
coated 12-mm-diameter coverslips (immunostaining) or glass bottomed MatTek dishes 
(functional imaging) at 12,000 - 15,000 cells/coverslip in DMEM-F12 medium 
supplemented with 0.6% glucose, 10% B27 (without vitamin A; Thermo Fisher Scientific), 
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1% Pen/Strep, 5 mM HEPES (Thermo Fisher Scientific), and 10 ng/mL brain derived 
neurotrophic factor (BDNF; Sigma). After 7 DIV, medium was exchanged gradually (50% 
on days 7 and 9) and then fully (100% every 72 - 96 h) to BrainPhysTM (STEMCELL 
Technologies Inc, Vancouver, BC, CAN) supplemented with SM1 (STEMCELL). 
HIV-1 propagation and HIVsup preparation.  
HIV-1BaL was propagated using methods previously established (Balinang et al., 
2017). Briefly, isolated PBMCs from peripheral blood Leuko Paks (ZenBio, Research 
Triangle Park, NC) were activated with 1 mg/mL phytohemagglutinin (PHA) for 48 h, then 
infected with HIV-1BaL (NIH AIDS Reagent Program) at 1 ng/mL p24. After 72 h, infection 
was assayed using p24 antigen ELISA kit (Advanced Bioscience, Rockville, MD) and 
supernatant harvested and frozen at −80° C for HIVsup experiments. HIVsup used in all 
experiments was from the same source sample to reduce variability. 
Treatments.  
hNeuron cultures were treated with HIVsup at 125 - 500 pg/mL [p24] or HIV protein 
(10 - 100 nM HIV-1 Tat1-86 IIIB (clade B) or 250 pM - 1 nM R5-tropic gp120ADA, X4-tropic 
gp120IIIB, or dual-tropic gp120 MN; ImmunoDx, Woburn MA) ± 500 nM morphine sulfate 
for 6 or 24 h. Drug treatments: 10 µM CLP257 (Sigma), 50 µM AP5 (Alomone Labs, 
Jerusalem IL), 50 nM maraviroc (MVC; BOC Sciences, Shirley, NY) were applied 30 min 
prior to HIVsup, HIV protein, and morphine for 24 h experiments. 50 µM VU02440551 
(Tocris, Bristol UK) was applied 2 h prior to GEVI/GECI imaging experiments. 
Supernatant from uninfected but activated monocytes (UNF) was used as a control for 
HIVsup. Vehicle controls were used for all other treatments. 
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Immunocytochemistry and Cell Counting.  
Neuronal cultures were fixed for 15 min (4% paraformaldehyde), permeabilized for 
15 min (0.1% Triton-X 100, 0.1% BSA) and blocked for 1 h at room temperature (0.1% 
BSA, 1% goat serum in PBS). Coverslips were then immunostained with rabbit anti-KCC2 
(1:1000; Protein Tech, Rosemont, IL) and mouse anti-microtubule-associated protein 
(MAP2) (1:500; Millipore, Burlington, MA) for KCC2 immunoreactivity studies Alexa Fluor 
488 and 594-conjugated secondary antibodies (1:1000; Thermo Fisher, Waltham, MA) 
were used for all studies as well as Hoechst 33342 (1:10000; Invitrogen, Carlsbad, CA) 
to detect nuclei. Cells were visualized and images obtained using a Zeiss LSM 700 
confocal module configured to an Axio Observer Z.1 and Zen 2010 software (Zeiss Inc., 
Thornwood, NY). Cells were manually counted using the CellCounter plugin for Image J. 
At least 200 Hoechst+ cells were counted per sample. 
GEVI/GECI Expression.  
AAV serotype 1 containing GCaMP6f and Archon1 were acquired from AddGene 
(plasmid # 100837; Watertown, MA) and Vector Biolabs (Malvern, PA), respectively. 
hNeurons were treated with AAV1.hSyn.GCaMP6f.WPRE.SV40 or 
AAV1.hSyn.Archon1.WPRE.SV40 for 5 - 7 days prior to experiments. Human synapsin 
promoter (hSyn) was used to ensure neuronal specificity. 
GEVI/GECI Imaging and Analysis.  
Archon1 and GCaMP6f recordings were acquired at 2 or 1 KHz, respectively, with 
a Neuro-CCD camera (RedShirt Imaging, Decatur, GA) mounted on a Zeiss Axio 
Observer with 40× oil immersion objective. Archon1 and GCaMP6f illumination was 
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achieved with an LED (UHP-T-LED; Prizmatix, Holon, IL) 640 nm excitation, 660LP 
emission for Archon1 (custom-made filter cube; Omega Optical, Brattleboro, VT) and 
470/40 nm excitation, 495 dichroic, 525/50 nm emission for GCaMP6f (filter set 38; Zeiss). 
All recordings were performed in BrainPhys solution (STEMCELL) with 2 µM CGP55845 
(GABABR antagonist; Abcam) or 2 µM CGP55845 and 100 µM picrotoxin (PTX) (GABAA 
and glycine receptor antagonist; Tocris) to validate Archon1 results (Fig. S3).  
Soma ROI were used for all experiments. Archon1 and GCaMP6f traces were 
analyzed with a custom code in R. Both Archon1 and GCaMP6f traces were 5-point 
Savitzky-Golay smoothed and GCaMP6f traces were Loess subtracted, to remove slower 
transients. Fluorescence changes were calculated as ΔF/F = (FA - Fbl)/Fbl, where FA is the 
fluorescence level during perfusion and Fbl is the average baseline fluorescence intensity 
2.5 s prior to perfusion. Significant Ca2+ transients were counted when the trace increased 
by more than four-fold of the standard deviation (SD) of background activity (measured 
2.5 s prior to perfusion) and returned to baseline levels (defined as within 0.5 × SD of 
mean activity). 
Animals.  
Male, doxycycline (DOX)-inducible, GFAP driven HIV-1 Tat-transgenic mice (10 – 
12 weeks old) were used to explore the effects of Tat expression on KCC2. Mice 
expressing the tat and rtTA transgenes (Tat+) or mice lacking the tat transgene, but 
expressing the rtTA transgene (Tat−), were fed doxycycline-containing chow (6 mg/g, 
Harlan Indianapolis, IN) for 2 weeks prior to sacrifice. Animal procedures were approved 
by the Virginia Commonwealth University Institutional Animal Care and Use Committee 
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and are in accordance with Association for Assessment and Accreditation of Laboratory 
Animal Care guidelines. 
Immunoblot.  
KCC2 presence was examined by immunoblotting striatal tissue from Tat+ and 
Tat- mice. Striata were freshly harvested and homogenized in RIPA lysis buffer (Sigma) 
and HaltTM Protease & Phosphatase Inhibitor Cocktail (Thermo Fisher). Lysates were 
then centrifuged and stored at -80º C. Protein concentration was measured using BCA 
protein assay (Pierce, Rockford, IL). 40 µg of lysates were loaded per well onto 4 – 20% 
Tris-HCl Ready Gels (Bio-Rad Laboratories, Hercules, CA). Proteins were transferred to 
PVDF membranes (Bio-Rad) and probed with antibodies against KCC2 (1:2000; Protein 
Tech) and GAPDH (1:2000; Abcam). Alexa Fluor 647 and 488-conjugated secondary 
antibodies (1:2000; Thermo Fisher) were used to detect proteins. A Bio-Rad ChemiDocTM 
MP Imaging System and Image Lab were used to measure and analyze protein levels, 
respectively. 
Statistics.   
KCC2 immunocytochemistry studies were assessed using three or two-way 
analysis of variance (ANOVA; R) to determine the effects of Tat1-86/gp120/HIVsup, 
CLP257/AP5/MVC, and morphine on KCC2 expression at 24 h following viral/drug 
exposure. The 6 h studies were assessed using two-way ANOVA with HIV (i.e., Tat1-86, 
gp120, or HIVsup) and morphine treatments as factors. Interactions and main effects for 
both were examined via simple main effects using a Bonferroni post hoc test to determine 
individual group differences. Functional imaging studies were analyzed as above except 
the assessment of VU0240551 was determined separately using a two-tailed Student’s t 
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test. A two-tailed Student’s t test was also used to examine differences between Tat+ and 
Tat− mice in western blots. Data were expressed as mean value ± standard error of the 
mean. Analyses were considered significant if p < 0.05. Cook’s distance was used to 
determine and remove outliers. 
Results 
HIV-1-infected PBMC supernatant reduces KCC2 immunoreactivity.  
Previous studies have shown selective vulnerability of GABAergic neurons to HIV-
1 and Tat (Marks et al., 2016, Gelman et al., 2012a). Here, we examined KCC2 
immunoreactivity to determine if [Cl−]i dysregulation might relate to GABAergic deficits. 
To model the HIV-infected human brain, we exposed hNeurons to HIVsup. Experiments 
show ~55 % of Hoechst+ cells in control groups are immunoreactive for KCC2 (Fig. 3.1A), 
with significant reductions in co-expression when hNeurons were exposed for 6 or 24 h 
to HIVsup at 250 - 500 pg/mL [p24] (but not 125 pg/ml [p24]) or 500 nM morphine (p < 
0.01; n = 6) (Fig. 3.1A,B). Loss of KCC2 was not due to cell death in the exposure groups 
examined as evidenced by continued MAP2 antigenicity and the LIVE/DEADTM 
viability/cytotoxicity assay (Molecular Probes, Eugene, OR) (Fig. 3.8). Pretreatment (30 
min prior to HIVsup ± morphine) with the KCC2 enhancer, CLP257 (10 µM), restored KCC2 
immunoreactivity (p < 0.05; n = 6) (Fig 3.1B). These results suggest that Cl− regulation 
and, therefore, GABA function may be altered in neurons of the HIV-1-exposed brain. 
HIVsup and morphine interactions were examined at 125 pg/mL p24, but not found). This 
interaction was not examined at 250 - 500 pg/mL p24 since cell death can occur with 
morphine co-exposure at the higher p24 levels (Masvekar et al., 2015) and which might 
be confounding for KCC2 immunoreactivity.   
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The HIV proteins Tat and gp120 are both well-known to influence neuronal 
hyperexcitability and progression of HAND (Nath and Steiner, 2014), so we tested their 
contribution to the loss in KCC2 immunoreactivity induced by HIVsup. Since NMDAR and 
CCR5 are respective major targets of Tat and gp120, we pretreated cultures with the 
NMDAR antagonist AP5 (50 µM) and/or the CCR5 antagonist, MVC (50 nM). Independent 
exposures showed that both significantly increase KCC2 immunoreactivity at 500 pg/mL 
HIVsup and AP5 at 250 pg/mL HIVsup (p < 0.05, n = 5 – 6) with a trend towards rescue with 
MVC at 250 pg/mL HIVsup (p = 0.061, n = 5 – 6) (Fig 3.1D). When combined, MVC and 
AP5 are significantly different than either individually and completely restored KCC2 
immunoreactivity (p < 0.01; n = 5 - 6) (Fig 3.1D), suggesting NMDAR and CCR5 as the 
pathways mediating HIVsup-induced KCC2 reduction. Further examination revealed a 
significantly increased KCC2 after AP5 exposure compared to MVC exposure suggesting 
that while both CCR5 and NMDAR activation play a role, NMDAR is the dominant 
pathway towards diminished KCC2 in this context (p < 0.01; n = 5). Both the pan-opioid 
receptor antagonist, naloxone, and the selective MOR antagonist, CTAP, reversed KCC2 
losses induced by morphine, suggesting MOR activation can suppress KCC2 activity (p 
< 0.01; n = 6) (Fig 3.1C). 
HIVsup ± morphine diminishes GABAAR mediated hyperpolarization.  
The GEVI, Archon1, is a far-red-shifted, membrane-bound, voltage-sensitive, 
opsin-based fluorescent protein that changes fluorescence intensity with membrane 
potential. This high speed, noninvasive measurement of electrophysiological activity was 
shown to be identical to patch-clamp recording of neuronal spiking (100 Hz) and 
subthreshold millivolt scale activity (Piatkevich et al., 2018). To determine HIVsup ± 
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morphine effects on GABAAR activation, we measured Archon1 activity in cultures 
perfused with 100 µM GABA and GABABR antagonist, CGP55845 (2 µM) after 24 h 
exposure to 125 - 500 pg/mL [p24] HIVsup ± morphine or to vehicle/UNF controls. Archon1-
expressing hNeuron control groups showed robust hyperpolarization with peak ΔF/F 
deflection of −8.7 ± 0.5% during 115 s perfusion of 100 µM GABA, CGP55845 (Fig. 3.2). 
hNeurons exposed for 24 h to varying concentrations of HIVsup (125 - 500 pg/mL p24) or 
morphine (500 nM) showed 16 - 34% reductions of peak ΔF/F deflection during perfusion 
(p < 0.01; n = 15 - 24), suggesting reduced hyperpolarization in response to GABAAR 
activation (Fig. 3.2). Analysis revealed a main effect of CLP257 treatment in restoring 
GABAAR-mediated hyperpolarization. A comparison of individual groups revealed that 
CLP257 reversed the effects of 500 pg/mL [p24] HIVsup and morphine (p < 0.05; n = 15 - 
24) (Fig. 3.2). Groups exposed to the KCC2 antagonist, VU0240551 (50 µM), 
recapitulated results of HIVsup and morphine groups (28% ΔF/F reduction; p < 0.05; n = 
15) (Fig. 3.2). We confirmed that ΔF/F changes above were, in fact, due to GABAAR 
activation by perfusing GABA, CGP55845, and the noncompetitive Cl- channel blocker, 
PTX (100 µM), and found no fluctuations in ΔF/F (Fig. 3.3). These results suggest that 
loss of KCC2 activity due to HIVsup ± morphine exposure results in dysregulated [Cl−]i and 
subsequent deficits in GABAAR activity, and that these deficits can be rescued by 
maintaining KCC2 expression with CLP257.  
HIV-1 proteins reduce KCC2 immunoreactivity.  
Since HIVsup contains multiple inflammatory and viral factors found in the HIV-
infected CNS, it served as a more translational model of neuronal injury. To determine 
the contribution of individual viral proteins to effects seen with HIVsup, we exposed 
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hNeurons to Tat1-86 and gp120 (R5-tropic, X4-tropic, and dual-tropic), both of which are 
thought to be primary factors in neurodegenerative outcomes and HAND symptoms. We 
first examined the effects of Tat1-86 exposure in isolation because NMDAR is a primary 
target of Tat and its activation with regard to induction of KCC2 degradation is well-known 
(Medina et al., 2014). Both morphine (500 nM) and Tat1-86 (50 – 100 nM) alone 
significantly reduced percentages of Hoechst+ cells displaying KCC2 immunoreactivity, 
after both 6 and 24 h exposure, compared to vehicle groups (p < 0.01; n = 6) (Fig. 3.4B, 
C). Further, there was a significant interaction between Tat1-86 (50 nM) and morphine with 
24 h co-exposed groups displaying exacerbated KCC2 loss (p < 0.05; n = 5 – 6), 
suggesting signaling convergence. Again, cell death was not responsible for Tat1-86 
effects since the number of MAP2+ cells was stable (Fig. 3.4A) and no increases in 
dying/dead cells were evident using a cytotoxicity assay (Fig. 3.8). CLP257 significantly 
rescued KCC2 immunoreactivity in Tat1-86, morphine, and co-exposed groups (p < 0.01; 
n = 6) (Fig. 3.4C). Pharmacological blockade of NMDAR with AP5 rescued KCC2 
immunoreactivity (Fig. 3.4C). These data suggest that Tat1-86 activation of NMDAR may 
suppress KCC2 levels and may play a role in reducing the number of HIVsup-exposed 
KCC2 immunoreactive hNeurons without causing their death. 
Effects on KCC2 vary with gp120 tropism.  
We tested concentration -dependent effects of gp120 (250 pM-1 nM) from three 
different tropic strains of HIV. Exposure to gp120ADA (R5-tropic; p < 0.01; n = 6), but not 
gp120IIIB (X4-tropic) (p = 0.23; n = 5) or gp120MN (dual-tropic) (p = 0.078; n = 5) strains, 
significantly reduced KCC2 expression at both 6 h and 24 h compared to controls (Fig. 
3.5 A, B). Further, there was a trend towards interaction with morphine and gp120ADA at 
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the 500 pM level (p = 0.068; n = 6). The reduction in KCC2 immunoreactivity was not due 
to cell death, although exposure to 1 nM gp120MN trended towards significant cell loss (p 
= 0.06; Fig. 3.8). While KCC2 is a well-studied target of NMDAR activation in other 
neuropathologic diseases, CCR5-mediated KCC2 regulation has not been described by 
others. To validate that CCR5 activation triggered KCC2 loss, we pretreated cultures with 
the CCR5 antagonist, MVC (50 nM), which maintained KCC2 expression (49.19 ± 1.2%; 
p < 0.01; n = 5). Interestingly, pretreatment with CLP257 did not rescue KCC2 
immunoreactivity in these experiments. These results describe a novel mechanism of 
KCC2 regulation involving CCR5 and suggest that the activation of CCR5 by gp120ADA 
may contribute to KCC2 reductions after HIVsup exposure. 
HIVsup, Tat, and gp120 ± morphine did not alter NKCC1 immunoreactivity.  
NKCC1 acts in opposition to KCC2 and is the primary neuronal Cl- transporter in the 
immature brain. To examine another potential route of neuronal Cl- dysregulation, we 
immunostained hNeurons for NKCC1 after 24 h exposure to 125 – 500 pg/mL [p24] 
HIVsup, 10 – 100 nM Tat, and 250 – 1000 pM gp120 ± morphine. NKCC1 was not 
detectable with exposure any of the viral factors or morphine at any of the concentrations 
examined (n = 4) (data not shown). 
HIV-1 proteins reduce inhibitory potential of GABAAR activation.  
We next examined the functional effects of Tat1-86, gp120ADA, and morphine on 
GABAAR-induced inhibition by expressing the intracellular Ca2+ reporter GCaMP6f in 
hNeurons using AAV1.hSyn.GCaMP6f.WPRE. GABAAR-mediated inhibition was 
examined in these cells by recording neuronal Ca2+ activity during perfusion of BrainPhys 
solution containing 100 µM GABA, 25 µM glutamate, and 2 µM CGP55845 for 55 s and 
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quantifying resultant neuronal spiking (the total number of significant Ca2+ transients 
during 55 s recording period). Analysis revealed a significant increase in 50 nM Tat1-86 
and morphine groups, without interaction comparedto vehicle (p < 0.01; n = 15 – 21) (Fig. 
3.6B). Thus, Tat1-86 and morphine independently reduced the inhibitory potential of 
GABAAR activation. Pretreatment with CLP257 ameliorated Tat1-86 and morphine effects 
(p < 0.01; n = 15 - 21), suggesting rescue of inhibitory activity in these groups, consistent 
with immunoreactivity results showing restored levels of KCC2. We also found 
disinhibition of hNeurons, as determined by significantly increased Ca2+ spiking in groups 
exposed to 500 pM gp120ADA (Fig. 3.6B). Three-way ANOVA revealed a main effect of 
gp120ADA regardless of CLP257 or morphine application (p < 0.05; n = 15 - 18). 
Pretreatment with MVC showed a strong tendency to prevent gp120-induced excitation 
presumably by retaining/restoring KCC2 function (p = 0.059). Consistent with 
immunoreactivity results, these results suggest a failure of CLP257 to maintain KCC2 
expression following gp120ADA exposure and, thus a failure to restore the inhibitory effects 
of GABAAR activation. Selectively inhibiting KCC2 with VU0240551 recapitulated the 
effects of Tat1-86 or gp120ADA ± morphine effects (n = 15, p < 0.01) independently 
confirming the role of KCC2 in the overexcitation. These results suggest that hNeurons 
become disinhibited after Tat1-86 or gp120ADA ± morphine exposure due to a loss of KCC2 
activity and that pharmacological maintenance of KCC2 can prevent or rescue the 
deleterious effects of Tat and/or morphine. 
Tat expression reduces KCC2 in the striatum of Tat-transgenic mice.  
HIV-1 Tat transgenic mice show neuropathology and behavioral deficits similar to 
PWH (Schier et al., 2017, Fitting et al., 2013). To examine if KCC2 abnormalities found 
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in culture could be seen in Tat-transgenic mice, we performed western blot analysis of 
striatal tissue after two weeks of Tat induction by DOX. Tat+ mice showed a significant 
decrease in total KCC2 levels compared to Tat− control mice (Fig. 3.7) (p < 0.05; n = 12). 
These results confirm that chronic Tat exposure induces KCC2 loss in vivo as well as in 
cultured hNeurons. 
Discussion 
Previous studies including human post-mortem (Buzhdygan et al., 2016, Gelman 
et al., 2012a) and in vivo rodent studies (Marks et al., 2016, Xu et al., 2016, Fitting et al., 
2013) have shown selective changes in GABAergic markers and function, driving an 
emerging concept that disrupted GABAergic transmission may be central to the 
development of HIV-related CNS dysfunction. Our data strengthen this perspective by 
demonstrating that KCC2 levels and subsequent GABAergic activity are diminished by 
an infective, HIV+ environment and by exposure to gp120ADA in vitro or HIV-1 Tat, both in 
vitro and in vivo. Importantly, HIV-infected individuals demonstrate a loss of GABAergic 
markers without the loss of GABAergic neurons (Buzhdygan et al., 2016) as seen in the 
present study. Taken together, our data along with findings from other investigators 
suggest that there may be an overall loss of inhibition via reduced inhibitory synapses 
and/or GABAergic function, and as we demonstrate here, diminished hyperpolarization 
at remaining inhibitory synapses caused by deficits in KCC2. 
Endogenous levels of chemokine (C-C motif) ligand 5 (CCL5) are almost 
undetectable in the healthy CNS, but dramatic increases are found in several 
neuroinflammatory disorders (Louboutin and Strayer, 2013) including HAND (El-Hage et 
al., 2005, Letendre et al., 1999). In multiple sclerosis, CCL5 is elevated during early 
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stages of the disease and is correlated with hyperexcitability (Sorensen et al., 1999, Mori 
et al., 2016). Our results demonstrate KCC2 as a target of CCR5 activation that may 
underlie this hyperexcitability. Targeting CCR5, perhaps with MVC, should be further 
investigated for therapeutic potential in multiple sclerosis and in other disorders in which 
elevated CCL5-CCR5 signaling may be operative, such as in neuroHIV (Kim et al., 2018).  
Additionally, our results using the MOR-selective antagonist, CTAP (Fig. 3.1C) 
demonstrate that neuronal KCC2 expression is a target of MOR activation. It is important 
to note that we have used a mixed neuron-astrocyte culture model. Outcomes may thus 
be due to direct activation of neuronal MOR, or a secondary effect of MOR activation on 
astroglia. Our results only demonstrated an interaction between morphine and viral 
proteins at the 24 h timepoint. Our previous studies have shown neurotoxic interactions 
between morphine and HIV/viral proteins at 24 – 72h and also that neurotoxicity was 
largely if not completely driven by glia (Zou et al., 2011) [or similarly by CCR5 deletion 
from glia (Kim et al., 2018)]. Thus, astrocytes may be acting as the intermediary through 
which MOR activation leads to neuronal KCC2 loss in the data presented here. Overall, 
our implication of MOR in KCC2 loss is in line with previous findings that GABAAR 
activation on neurons in the ventral tegmental area of rats switches from an inhibitory to 
excitatory signal during the development of opiate dependency (Laviolette et al., 2004, 
Vargas-Perez et al., 2009), and that KCC2 loss contributes to states of opiate withdrawal 
and morphine-induced hyperalgesia via mechanisms involving microglia-mediated BDNF 
release and subsequent TrkB activation (Ferrini et al., 2013, Ferrini et al., 2017, Taylor et 
al., 2016). Further, we found an exacerbation of KCC2 losses at 50 nM Tat with co-
exposure to morphine, suggesting that opiates and HIV protein interactions may similarly 
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occur in the CNS and underlie the increased incidence/severity of HAND that has been 
noted in PWH who abuse opiates (Byrd et al., 2011, Bell et al., 2006, Carrico, 2011, Smith 
et al., 2014). 
Interestingly, CLP257 was able to maintain KCC2 expression and functional 
response of hNeurons to Tat, but had no effect on gp120-exposed groups. While many 
factors regulate KCC2 activity/degradation, the mechanism by which CLP257 preserves 
KCC2 activity remains elusive. KCC2 stability is regulated by phosphorylation at multiple 
sites. For example, phosphorylation of S940 or T1007 by protein kinase C and WNK 
increases and decreases KCC2 membrane stability, respectively (Lee et al., 2011, Inoue 
et al., 2012). NMDAR activation can lead to protein phosphatase 1 activation and S940 
dephosphorylation leading to decreased membrane localization and subsequent calpain-
induced KCC2 degradation in the cytoplasm (Lee et al., 2011). Thus, there are several 
mechanisms that may underlie the effects of CLP257. gp120 and Tat may have 
differential effects on one or more of these pathways, resulting in these inconsistencies. 
MVC, an FDA-approved CCR5 antagonist commonly prescribed to HIV-infected 
individuals to prevent HIV from binding to this co-receptor, was able to rescue both KCC2 
expression and functional responses to GABAAR activation in gp120ADA-exposed 
hNeurons. Thus, MVC treatment might prevent gp120ADA-induced KCC2 loss upstream 
of CLP257 and could be considered more widely for PWH with HAND symptomology.  
Neuronal electrophysiological properties govern CNS function, and elucidating 
deficits at the cellular level can identify circuitry imbalances that underlie neurological 
disorders. To study electrophysiological responses in HIV-1 exposed neurons, we used 
the GEVI, Archon1. This noninvasive interrogation has the advantages of allowing 
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ensemble activity to be studied both in vitro and in vivo, with the capability of tracking 
specific neurons long-term. This is a particularly useful alternative to traditional 
electrophysiology when biosafety is a concern. Most of the experiments here utilized 
acute exposure paradigms (6 and 24 h). While this approach allowed us to uncover novel 
targets and subsequent functional responses in primary human neurons, PWH are 
exposed to these factors over a much longer timeframe. Thus, we began to validate the 
observed changes using a chronic in vivo model and found reduced KCC2 in the striatum 
of Tat+ transgenic mice after 2 weeks of Tat exposure. Further studies are underway to 
test the effectiveness of a CLP257 prodrug (CLP290) to reverse KCC2 loss, the resultant 
electrophysiological and behavioral changes observed with Tat and/or CLP290 
exposures, and any preferential vulnerability between the prominent neuronal subtypes 
in the striatum (dopamine D1 receptor-expressing vs. dopamine D2 receptor-expressing) 
to KCC2 loss. Interestingly, the loss of the expression of GABAergic markers is inversely 
correlated with increases in dopamine D2 receptor (DRD2L) in PWH  and increases in 
DRD2L in the prefrontal cortex positively correlated with the development of HAND 
(Gelman et al., 2012b, Buzhdygan et al., 2016). HIV-induced neurocognitive detriments 
vary among individuals, and length of exposure is likely a contributing factor along with 
age, genetics, comorbidities (including drug use), and the particular strains of HIV 
present. We used the HIVBaL strain to generate HIVsup as R5 tropism is prominent in the 
CNS (Schnell et al., 2011). We also began to address viral heterogeneity by comparing 
effects of three different gp120 strains. Results here suggest that R5-tropic strains may 
be more likely to disrupt GABAergic circuitry. CSF viral titers and levels of HIV-1 Tat have 
been shown to vary among infected individuals whose blood titers are well-controlled 
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(Johnson et al., 2013, Henderson et al., 2019). Thus, we expect that levels of viral proteins 
and inflammation within the brain parenchyma must also vary among PWH. As these 
levels are not easily measured, our experimental paradigm may over- or underestimate 
CNS exposure levels in HIV-infected individuals.  
Similar situations of disinhibition through dysregulated [Cl−]i appear to contribute 
significantly to hyperexcitability in other neurological disorders, and restoration of KCC2 
with CLP257 or its prodrug, CLP290, has shown promise in reversing the hyperexcitability 
in models of these disorders (Chen et al., 2018, Ferrini et al., 2017). Overall, our studies 
further implicate KCC2 in novel ways that could have broad impact for human health. We 
established KCC2 and upstream pathways as promising therapeutic targets to restore 
GABAergic function and to treat the symptoms of HAND, and this approach may be 
particularly relevant for PWH that use opiates. We also identified KCC2 as a novel link 
underlying hyperexcitability in conditions that involve elevated CCL5 and/or CCR5 
activation in the CNS. Our results also highlight that opiate drugs of abuse may 
independently dysregulate KCC2 levels to cause GABAergic dysfunction. This finding has 














Figure 3.1. HIVsup and morphine significantly reduce the percentage of cells 
immunoreactive for KCC2. Treatment for 6 h (A) or 24 h (B) with 250 – 500 pg/mL 
[p24] HIVsup ± morphine significantly reduces the number of KCC2 immunoreactive 
cells (†p < 0.01 for respective controls; n = 6). CLP257 (blue) rescued this effect across 
all groups (*p < 0.05, n = 6). Naloxone and CTAP both antagonized the effects of 
morphine (C), suggesting the involvement of MOR (*p < 0.01; n = 6). AP5 (orange) 
restored KCC2 immunoreactivity after 250 – 500 pg/mL HIVsup exposure while MVC 
(maroon) significantly increased KCC2 in 500 pg/mL (*p > 0.05, n = 5 – 6). A trend 
towards MVC rescue of KCC2 immunoreactivity was found at 250 pg/mL HIVsup (p = 
0.061, n = 5 – 6). Co-exposure of HIVsup with both AP5 and MVC fully restored KCC2 
levels, suggesting NMDAR and CCR5 as the primary pathways of HIVsup-mediated 
KCC2 reduction. Representative images for KCC2 immunofluorescence of vehicle, 






















Figure 3.2. HIVsup and morphine decrease GABAAR-mediated hyperpolarization. 
(A) Representative traces of 500 pg/mL [p24] HIVsup treated (red) and vehicle control 
(black) during GABA and CGP55845 perfusion (115 s). Arrow is representative of the 
diminished hyperpolarization quantified in the bar graph. (B) Bar graph shows peak 
ΔF/F deflection from each treatment groups normalized as a percentage of vehicle 
control corresponding to that sample during 115 s perfusion of 100 µM GABA and 
CGP55845. hNeurons expressing Archon1 exposed to 125 - 500 pg/mL [p24] HIV ± 
morphine shows reduced hyperpolarization (†p < 0.01, n = 15 - 21) and/or UNF (ǂp < 
0.01, n = 15 - 21). Analysis revealed a main effect of CLP257 and group comparisons 
showed that CLP257 significantly reversed the effects of 500 pg/mL HIVsup and 
morphine groups (blue) (*p < 0.05, n = 15 - 21). Further, 2 h treatment with 
VU02440551 showed similar results as HIVsup ± morphine groups, significantly 
reducing percentage of cells immunoreactive for KCC2 (#p < 0.05, n = 15 - 21), 
suggesting that effects of HIVsup and morphine are due to loss of KCC2 activity. Data 







Fig. 3.3. Validation of Archon1.  Representative trace of Archon1 activity in hNeuron 
during perfusion of 100 µM GABA and CGP55845 (Top) and 100 µM GABA and 
CGP55845 and PTX (bottom). Antagonizing GABAAR and GABABR prevented ΔF/F 
changes, suggesting that fluorescence shifts seen in the top trace and Fig. 3.2 are due 















Figure 3.4. hNeurons lose KCC2 immunoreactivity after exposure to HIV-Tat ± 
morphine. (A) Representative images of hNeuron cultures immunolabeled for MAP2 
and KCC2. Loss of KCC2 immunoreactivity can be noted in cells treated with both 50 
nM Tat1-86 and 50 nM Tat1-86 + morphine. Rescue is seen in 50 nM Tat1-86 + AP5 (scale 
bar = 50 µm). (B, C) The percentage of cells immunoreactive for KCC2. Both 6 h (B) 
and 24 h (C) exposure to 50 - 100 nM Tat1-86 ± morphine results in significant decrease 
in KCC2 immunoreactivity compared to their respective controls (†p < 0.01; n = 6 – 7). 
Further, a significant interaction between morphine and Tat1-86 was found at the 50 nM 
Tat1-86 level after 24 h exposure (#p < 0.05). Application of CLP257 (blue) and AP5 
(white) showed significant restoration of KCC2 immunoreactivity across all groups and 







Figure 3.5. gp120 ADA reduces KCC2 immunoreactivity. (A, B) Bar graphs 
quantifying percentage of cells immunoreactive to KCC2. Both 6 h (A) and 24 h (B) 
exposures to 500 pM - 1 nM gp120 ADA significantly reduced the percentage of KCC2 
immunoreactive cells compared to their respective controls (†p < 0.01; n = 6), while 
gp120 IIIB or gp120 MN had no significant effect on KCC2 expression. Interestingly, 
CLP257 co-exposure failed to maintain KCC2 immunoreactivity in gp120 ADA 
exposed groups, but MVC showed significant rescue (*p < 0.05; n = 5 - 6), suggesting 


















Figure 3.6. Tat1-86, gp120 ± morphine exposure decreased GABAAR mediated 
inhibition. (A) Representative 30 s sample GCaMP6f traces of vehicle (top) and 50 
nM Tat1-86 + morphine (bottom) exposed hNeurons during 25 µM glutamate, 100 µM 
GABA, and CGP55845 perfusion. (B) Exposure to 50 nM Tat1-86 ± morphine (500 nM) 
resulted in significantly increased Ca2+ transients measured by GCaMP6f activity 
during 55 s perfusion of 25 µM glutamate, 100 µM GABA, and CGP55845 compared 
to control (†; p < 0.05; n = 15 - 21). CLP257 (blue) rescued these effects (*; p < 0.01; 
n = 15 - 21). Exposure to 500 pM gp120 ADA showed significant increase in neuronal 
activity, regardless of CLP257 or morphine cotreatment (†; n = 15 - 21; p < 0.05). MVC 
exposure trended towards reversing gp120 effects (p = 0.059, n = 18). KCC2 
antagonist, VU02440551 recapitulated results of Tat1-86, gp120, and morphine, 
suggesting that these effects are due to loss of KCC2 activity (#p < 0.01, n = 15). Ca2+ 
transients were considered significant and counted when the spike amplitude was > 4 
SD above background activity (determined 2.5 s prior to perfusion; red line) and 













Figure 3.7. Tat+ mice show reduced striatal KCC2 compared to control Tat- mice.  
Two weeks of Tat expression significantly reduced the amount of KCC2 detected by 








Fig. 3.8. HIVsup, Tat, gp120 ± morphine effects on cellular viability. Treatments for 
24 h of 125 – 500 pg/mL [p24] HIVsup, 50-100 nM Tat ± 500 nM morphine had no 
significant effect on cellular viability (A, B). Treatments for 24 h of 250 – 1000 pM 
gp120 ADA and 1 nM gp120 IIIB do not affect cellular viability while 1 nM gp120 




Restoration of KCC2 membrane localization in striatal D2R-expressing medium 
spiny neurons rescues behavioral deficits in HIV Tat-transgenic mice 
(This chapter is in preparation for publication) 
 
Abstract 
People infected with HIV (PWH) are highly susceptible to hippocampal and striatal 
damage from the neurotoxic HIV protein, transactivator of transcription (Tat). Memory and 
motor impairment are common among these patients, likely as behavioral manifestations 
of damage to these brain regions. GABAergic dysfunction from HIV infection and Tat 
exposure has been well documented. We recently demonstrated that the neuron specific 
Cl- extruder, K+ Cl- cotransporter (KCC2), is diminished after exposure to HIV proteins 
resulting in disrupted GABAAR-mediated hyperpolarization and inhibition. Here, we 
utilized doxycycline (DOX)-inducible, GFAP-driven Tat transgenic mice to further explore 
this phenomenon. We found no changes in hippocampal KCC2, but a significant decrease 
in the striatum associated with hyperlocomotion in the open field assay in mice expressing 
the Tat transgene with two wks of DOX treatment. We were able to restore KCC2 activity 
and baseline locomotion with the KCC2 enhancer, CLP290. Additionally, we found that 
CLP290, whose mechanism of action had yet to be described, acts to restore 
phosphorylation of serine 940 resulting in increased KCC2 membrane localization. We 
also examined neuronal subpopulation contributions to the noted effects and found that 
dopamine receptor D2-expressing MSNs are selectively vulnerable to Tat-induced KCC2 
75 
 
loss with no changes seen in dopamine receptor D1-expressing MSNs. These results 
provide a mechanism underlying motor impairment in PWH and suggest that targeting 
KCC2, perhaps with CLP290, is a viable treatment for those with HIV-associated 
neurocognitive disorders. 
Introduction 
While the advent of combined antiretroviral therapy (cART) has greatly improved 
the prognosis of HIV-1 infection, quality of life issues remain. One of the most prevalent 
being HIV-associated neurocognitive disorders (HAND), with about half of people infected 
with HIV (PWH) experiencing detriment in varying neurocognitive domains including 
memory recall and sensorimotor function (Heaton et al., 2010, Antinori et al., 2007). 
These cognitive and behavioral alterations are likely due to synaptodendritic damage and 
circuitry disruption caused by direct and secondary damage from HIV proteins and 
persistent neuroinflammation (Masliah et al., 1997, Brailou et al., 2008, Tavazzi et al., 
2014, Alakkas et al., 2019). While neurons are not infected by HIV, both microglia and 
astrocytes can be infected and release viral proteins and inflammatory factors damaging 
neurons as bystanders. Both the hippocampus and striatum seem to be particularly 
vulnerable to these factors in humans and in vivo models of HAND (Fitting et al., 2010, 
Marks et al., 2016, Fitting et al., 2013, Gelman et al., 2006, Chang et al., 2008, Maki et 
al., 2009, Alakkas et al., 2019). 
The HIV-1 protein, transactivator of transcription (Tat), is a primary mediator of 
HIV-induced CNS degeneration, is secreted by infected cells, and its expression is seen 
in PWH even when receiving effective cART (Henderson et al., 2019). Use of the 
doxycycline (DOX)-inducible, glial fibrillary acidic protein (GFAP)-driven Tat transgenic 
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mouse has been used to study the neuropathological features of Tat exposure in vivo and 
recapitulates many of the behavioral abnormalities seen in HAND patients (Paris et al., 
2014b, Hahn et al., 2016, Fitting et al., 2012, Marks et al., 2016, Fitting et al., 2013, Carey 
et al., 2012, Kim et al., 2003). Tat is capable of inducing proinflammatory phenotypes in 
both astrocytes and microglia, promoting neuroinflammation and has direct neuronal 
targets. Through activation of NMDAR, AMPAR, L-type voltage gated Ca2+ channels, Tat 
can induce focal disruptions in Ca2+ homeostasis resulting in loss of synaptodendritic 
complexity (Fitting et al., 2014, Schier et al., 2017, Fitting et al., 2010, Chandra et al., 
2005, Napier et al., 2014).  
Hyperexcitability is a hallmark of the HIV-exposed CNS and excessive glutamate 
release and reduced clearance have been well studied (Longordo et al., 2006, Pappas et 
al., 1998, Wang et al., 2003, Musante et al., 2010). Accumulating evidence has also 
revealed the importance of GABAergic disruption in hyperexcitability. Human postmortem 
tissue from HAND patients as well as in vivo models of HAND display reduced GABAergic 
markers (Fitting et al., 2013, Marks et al., 2016, Buzhdygan et al., 2016, Gelman et al., 
2012a) and functionality (Xu et al., 2016) as we also demonstrated in Chapter 3. K+ -Cl- 
cotransporter 2 (KCC2) is neuron-specific and functions to extrude Cl- to maintain low the 
intracellular levels upon which GABAAR mediated hyperpolarization is predicated. 
Membrane localization and, therefore, functionality of KCC2 is mediated by several 
phosphorylation sites (Cordshagen et al., 2018). One well-studied residue, serine 940 
(S940), can be phosphorylated by protein kinase C (PKC) to increase membrane stability 
and localization and can be dephosphorylated by protein phosphatase 1 (PP1) resulting 
in internalization (Lee et al., 2007, Lee et al., 2011). A loss of KCC2 and/or its membrane 
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localization results in diminished GABAAR-mediated hyperpolarization/inhibition and has 
been found to be a mediator of neuronal disinhibition in several neurological disorders 
(Lizhnyak et al., 2019, Arion and Lewis, 2011, Boulenguez et al., 2010, Chen et al., 2017a, 
Dargaei et al., 2018, Chen et al., 2017b). Importantly, these deficits have been rescued 
in many cases with the KCC2 activity enhancer, CLP257, and its prodrug, CLP290, 
although the mechanism underlying their mechanism of action remains elusive. We have 
recently shown that KCC2 is a target of the HIV proteins Tat and gp120 in primary human 
neurons in vitro and in an in vivo model of neuroHIV and, thus, may be implicated in 
neuronal dysfunction underlying HAND. 
The striatum is composed primarily of dopamine receptor D1 (D1R)-expressing 
medium spiny neurons (MSNs) and dopamine receptor D2 (D2R)-expressing MSNs. This 
area is particularly vulnerable to HIV-induced damage in PWH (Gelman et al., 2006, 
Alakkas et al., 2019), and in vivo models of neuroHIV (Fitting et al., 2014, Schier et al., 
2017, Fitting et al., 2010). Striatal MSNs, particularly those expressing D2R (Schier et al., 
2017) are vulnerable to Tat-induced spine reductions due to dendritic Ca2+ influx (Fitting 
et al., 2014). Given striatal vulnerability to Tat-induced KCC2 loss, and clinical evidence 
demonstrating motor deficits in PWH, we sought to further explore this phenomenon by 
examining potential motor dysfunction caused by diminished striatal KCC2, whether these 
effects were reversible using CLP290, and if there was preferential vulnerability between 
D1R-expressing or D2R-expressing MSNs. We found a loss of KCC2 selectively in D2R-
expressing MSNs of the striatum of mice expressing the Tat transgene (Tat+) vs those 
without the transgene (Tat-), correlating with motor hyperactivity after two wks DOX 
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administration. Additionally, we were able to rescue phosphorylation of S940-KCC2, 
membrane localization of KCC2, and motor activity with CLP290 oral gavage.  
Methods 
Animals 
All animal procedures were approved by the Institutional Animal Care and Use Committee 
at Virginia Commonwealth University and were in accordance with ethical guidelines 
defined by the National Institutes of Health. 
Mice used for behavioral and western blot experiments were male, doxycycline (DOX)-
inducible, GFAP driven HIV-1 Tat-transgenic mice aged 10 – 12 weeks. Mice that 
expressed the rtTA and Tat transgenes (Tat+) or mice only expressed rtTA without Tat 
(Tat-), were fed DOX-containing chow (6 mg/g, Harlan indianapolis, IN) for two weeks 
prior to experimentation.  
Tat+ and Tat- mice were crossed with B6.Cg-Tg (Drd1a-tdTomato)6Calak/J line 6 mice 
(#016204; The Jackson Laboratory) or Drd2-eGFP (#036931 – UCD; Mutant Mouse 
Resource and Research Centers) mice (Ade et al., 2011) to detect D1R-expressing and 
D2R-expressing neuronal subpopulations, respectively, and were used for 
immunohistochemistry (IHC)/colocalization and electrophysiological experiments. 
All mice were housed two to five per cage with ad libitum access to food and water in a 




Mice were treated with either the KCC2 enhancer, CLP290 (50 mg/kg; Aobious), freshly 
suspended in dimethyl sulfoxide (DMSO) and 20% 2-hydroxypropyl-β-cyclodextrin 
(HPCD; Tocris) or vehicle once per day (morning) by oral gavage (200 µL total volume) 
for seven days during the second week of DOX administration. 
Behavior 
After two weeks DOX administration, mice were assayed for locomotor effects with the 
open field assay by placing mice in the top left corner of a 40 x 40 x 35 cm Plexiglas box 
and recording their activity for 20 min. Rearing responses were recorded when the animal 
breaks the array of photo-beams and total distance and time spent in center was recorded 
and encoded using the ANY-maze behavioral tracking system (Stoelting). 
Western Blot 
KCC2 was quantified by western blot of striatum from Tat+ and Tat- mice. Freshly 
harvested whole striata were homogenized in RIPA buffer (Sigma) with HALTTM Protease 
& Phosphatase inhibitor Cocktail (Thermo Fisher) to prevent protein degradation. Lysates 
were separated and stored at -80º C. Protein concentration was measured using BCA 
protein assay (Pierce, Rockford, IL). 40 µg lysate per sample were loaded into 4 – 20% 
Tris-HCl Ready Gels (Bio-Rad Laboratories, Hercules, CA). Proteins were transferred to 
PVDF membranes (Bio-Rad) and probed with anti-KCC2 (1:2000; Protein Tech, 
Rosemont, IL) or anti-pS940 KCC2 and GAPDH (1:2000; Abcam) antibodies. KCC2 and 
GAPDH proteins were detected measuring fluorescent signal from Alexa Fluor 647 and 
488-conjugated secondary antibodies (1:1000; Thermo Fisher), respectively. pS940-
KCC2 proteins were detected using pS940-KCC2 specific antibody (1:2000; Novus Bio), 
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horseradish peroxidase (HRP; Southern Biotech; Birmingham AL) and SuperSignalTM 
West Femto Maximum Sensitivity Substrate (Thermo Fisher). 
Membrane bound KCC2 was examined by western blot by first performing membrane 
fractionation on striata from Tat transgenic mice. Briefly, tissue was homogenized in lysis 
buffer (4 mM HEPES (N-2-hydroxyethylpiperazine-N-3-ethane sulfonic acid; Thermo 
Fisher Scientific), 320 mM sucrose, 5 mM EDTA (ethylenediaminetetraacetic acid; 
Thermo Fisher Scientific), and HALTTM Protease & Phosphatase inhibitor cocktail 
(Thermo Fisher Scientific)), centrifuged at 100,000 x g, and the pellet containing 
membrane fraction was resuspended in lysis buffer and stored at -80º C. Protein 
concentration measurement and western blot for these samples were performed as 
above, except that a 20-µg lysate load was used per sample lane. KCC2 was normalized 
to total lane protein detected by RevertTM 700 Total Protein Stain (LI-COR, Lincoln, NE), 
and Alexa Fluor 488-conjugated secondary antibodies (Thermo Fisher) were used to 
detect KCC2. 
IHC 
After two wks DOX administration, Drd1a-tdTomato/Drd2-eGFP X Tat+/Tat- mice were 
fixed by cardiac perfusion with 4% paraformaldehyde (PFA). Brains were then dissected, 
submerged in 4% PFA for 24 h, washed in PBS, and sequentially placed in 10%, 20%, 
and 30% sucrose for 24 h each before being embedded in OCT. Serial 20 µM sections 
were cut on a cryostat, thaw mounted, dried, and stored frozen at -80º C. IHC was then 
performed by permeabilizing for 30 min (0.01% Triton-X100), blocking for 1 h, and 
overnight incubation with primary antibody for KCC2 (1:500; Protein Tech) at 4º C. The 
following day, Drd1a-tdTomato and Drd2-eGFP sections were washed and incubated for 
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1 h with 488 and 594 Alexa-Fluor conjugated secondary antibodies (1:1000; Invitrogen, 
Carlsbad, CA), respectively, for 1 h. Hoechst 33342 (1:10000, Thermo Fisher) was used 
to identify nuclei and weighted coverslips were adhered with ProLongTM Gold Antifade 
Mountant (Thermo Fisher). 
Colocalization 
To visualize KCC2 immunofluorescence and tdTomato or eGFP, Z-stack images were 
obtained with a Zeiss LSM 700 confocal module configured to an Axio Observer Z.1 with 
20 x objective and Zen 2010 software (Zeiss Inc., Thornwood, NY). 3D reconstruction 
and colocalization between KCC2 and tdTomato (D1R-expressing MSNs) or eGFP (D2R-
expressing MSNs) was performed with Imaris software (Bitplane, South Windsor, CT). 
Colocalization thresholding was determined using secondary control (without primary 
antibody incubation) sections from the same mice. Thresholds were equivalent across all 
mice and set to virtually no colocalization (< 1%) between tdTomato/eGFP and KCC2 
immunofluorescence for control slices. Colocalization results are displayed as the 
percentage of voxels with tdTomato or eGFP fluorescence colocalized with voxels 
containing KCC2 immunofluorescence. 
Statistics 
A two-tailed Student’s t test was used to examine potential differences in KCC2 western 
blots between Tat+ and Tat- mice and for colocalization experiments. Two-way analysis 
of variance (ANOVA) was used to examine behavioral assays and western blots with drug 
(CLP290/Vehicle) and genotype (Tat+/Tat-) as factors. Interactions and main effects were 
examined via simple main effects using Bonferroni post hoc test to determine group 
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differences. Data are displayed as mean value ± standard error of the mean. Results were 
considered significant when p < 0.05. All statistical analyses were performed in R.  
Results 
Two weeks of DOX-induced Tat expression reduces total KCC2 in the striatum of 
Tat-transgenic mice.  
Clinical evidence and results from Tat-transgenic mice have demonstrated 
vulnerability of the striatum and hippocampus to HIV- and Tat-induced neuropathology. 
Thus, we examined total KCC2 by western blot in hippocampal and striatal tissue from 
Tat-transgenic mice with DOX administration for two and four weeks (striatum) or two, 
four, and eight weeks (hippocampus). There was no difference found in hippocampus at 
any time points (two wk DOX: p = 0.82, n = 6; four wk DOX: p = 0.51, n = 6; eight wk 
DOX: p = 0.65, n = 7) (Fig 4.1A).  Nor were significant differences found in the striatum 
after four wks of DOX-induced Tat exposure (p = 0.28, n = 6) (Fig 4.1B). However, we 
found a significant decrease in total KCC2 in the striatum of Tat+ mice compared to Tat- 
mice on DOX for two wk (p = 0.001, n = 11 - 12) (Fig 4.1B; data also shown in Fig 3.8, 
included here for clarity). These results suggest that the striatum is vulnerable to Tat-
induced KCC2 loss in a biphasic, or possibly, more complex manner. This suggests that 
striatal circuitry may be disrupted due to deficits in GABAAR-mediated inhibition after two 
wks of Tat exposure. 
Tat expression reduced total KCC2 in the striatum and CLP290 rescued pS940-
KCC2 and KCC2 membrane localization.  
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To determine if striatal KCC2 loss could be reversed, we treated Tat+ and Tat-  
mice with 50 mg/kg CLP290 or vehicle by oral gavage once per day during the second 
week of DOX administration. Western blot analysis revealed a main effect of genotype to 
reduce total KCC2 in the striatum of Tat+ compared to Tat- mice without interaction (main 
effect: p = 0.002, n = 12 – 18), suggesting that Tat induction diminished the presence of 
KCC2 and that CLP290 failed to rescue total KCC2 levels (Fig 4.2A). Membrane 
localization of KCC2 and, thus, Cl- extrusion activity is promoted by phosphorylation of 
S940. We sought to determine if CLP290 treatment was capable of rescuing 
phosphorylation of S940 (pS940). Analysis of western blot of striata harvested from Tat+ 
and Tat- mice treated with either CLP290 or vehicle for pS940-KCC2 revealed a drug by 
genotype interaction (p < 0.05, n = 8 – 12). Investigation of simple main effects determined 
that Tat expression reduced pS940-KCC2 and administration of CLP290 rescued this 
effect (p < 0.05; n = 8 - 12) (Fig 4.2B) and, thus, likely restores membrane localization 
and Cl- extrusion capacity of KCC2. To confirm this, we performed a membrane fraction 
separation and western blot for KCC2 and found that membrane localization of KCC2 
was, again, significantly reduced by two wks Tat exposure and was, in fact, restored by 
CLP290 administration (p < 0.05, n = 8 – 9) (Fig 4.2C). These data suggest that CLP290 
is able to rescue the functional state of KCC2 and provide insight into a mechanism 
involving phosphorylation of S940 that may underlie the effects of CLP290. 
Tat+ mice displayed hyperactive locomotion with rescue seen via CLP290 
administration. 
To determine potential behavioral manifestations of Tat effects on disrupted striatal 
activity, we assayed locomotor activity of Tat+ and Tat- mice treated with either CLP290 
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or vehicle with the open field test. Significant increases were found in the distance 
travelled and rearing number in the Tat+/Veh groups with rescue in the Tat+/CLP290 
group (p < 0.05, n = 8 – 9) (Fig 4.3 A, B). These results suggest motor hyperactivity in 
Tat+ animals with CLP290 restoration of KCC2 membrane localization sufficient to 
restore baseline activity. We also examined the time spent in center zone as one measure 
of anxiety-like behavior and found no significant differences (n = 8 – 9) (Fig 4.3C). Overall, 
these results suggest that diminished KCC2 activity in the striatum, likely resulting in 
neuronal disinhibition, leads to excessive locomotion.  
Previous work in our lab demonstrated a loss in dendritic spines selectively in D2R-
expressing MSNs of Tat+ mice (Schier et al., 2017). Given the biochemical and behavioral 
results presented here and the role KCC2 plays in dendritic spine maintenance (Li et al., 
2007, Fiumelli et al., 2013), we hypothesized that D2R-expressing MSNs are selectively 
vulnerable to Tat-induced KCC2 loss, contributing towards disrupted striatal circuitry 
manifesting as hyper locomotor activity. 
D2R-expressing MSNs show enhanced KCC2 loss in response to Tat induction 
compared to their D1R-expressing counterparts.  
We crossed Tat+ and Tat- mice with Drd1a-tdTomato and Drd2-eGFP mice to 
allow for independent examination of D1R-expressing and D2R-expressing MSNs to 
determine if there is a preferential vulnerability of D1R or D2R-expressing MSNs to Tat-
induced KCC2 loss. To visualize KCC2 colocalization with tdTomato (D1R-expressing 
MSNs) or EGFP (D2R-expressing MSNs) we performed IHC with antibodies specific for 
KCC2 and either 488 or 594 secondary antibodies, respectively. Z stacks of striata were 
obtained and 3D reconstruction and subsequent colocalization analysis was performed 
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with Imaris. We found a loss of KCC2 colocalization with eGFP in Tat+ x Drd2-eGFP mice 
compared to Tat- x Drd2-eGFP mice (p < 0.05, n = 8) and no significant changes in KCC2 
colocalization between Tat+/Tat- x Drd1a-tdTomato mice (n = 3 – 12) (Fig 4.4). It does 
not appear that there is overt, total loss of KCC2 in some D2R-expressing MSNs, thus, 
there is likely a more subtle decrease across a large proportion. Particularly noticeable is 
that somatic KCC2 staining appears primarily around the membrane in D1R-expressing 
MSNs and Tat- D2R-expressing MSNs (yellow arrows, Fig 4.4), this localization is lost in 
Tat+ D2R-expressing MSNs (white arrows, Fig 4.4), suggesting shifted reversal potential 
of Cl- and diminished hyperpolarization in this population of neurons. Overall, data from 
these experiments suggest a preferential vulnerability D2R-expressing MSNs to Tat-
induced KCC2 loss and provide some insight to the circuit disruption underlying the 
behavioral abnormalities found above. 
Discussion 
These studies highlight a novel route of Tat-mediated neuronal damage to induce 
motor dysfunction. Loss of KCC2 detection was associated with motor hyperactivity after 
two wks of DOX-induced Tat exposure and we found preferential vulnerability of D2R-
expressing MSNs. Importantly, we were able to rescue membrane-localized KCC2 and 
behavioral abnormalities with the KCC2 activity enhancer, CLP290, demonstrating the 
potential efficacy of KCC2 as a therapeutic target for the treatment of HAND.  
The classic striatal model of motor initiation involves a balance between activation 
of the D1R-expressing MSN-mediated ‘Go-pathway’ and D2R-expressing MSN-mediated 
‘No Go-pathway’ (Gerfen and Young, 1988, Kravitz et al., 2010). Based on this model, 
we would expect to have seen a preferential vulnerability of D1R-expressing MSNs to 
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Tat-induced KCC2 loss resulting in disinhibition of the D1R-mediated ‘Go pathway’ of 
motor initiation. Our data do not support this hypothesis of motor initiation and lend 
credence to the growing body of evidence refuting this model. Recent prevailing theories 
suggest more subtle circuitry underlying striatal motor initiation and have demonstrated 
increased D1R- and D2R-expressing MSN activity during movement (Parker et al., 2018, 
Cui et al., 2013, Klaus et al., 2017, Barbera et al., 2016, Kupchik et al., 2015). Thus, 
disinhibition of either D1R- or D2R-expressing MSNs may lead to abnormal locomotion 
and as our data suggest, D2R-expressing MSN disinhibition induces motor hyperactivity 
in the open field assay. 
Motor impairment in PWH was initially described in the first publication outlining 
neurocognitive decline associated with HIV (Navia et al., 1986) and has persisted into the 
era of cART treatment (Valcour et al., 2008, Heaton et al., 2010, Robinson-Papp et al., 
2008). Typically, HIV-induced motor deficits are associated with hypokinetic symptoms 
such as bradykinesia (Mirsattari et al., 1998, Bhidayasiri and Tarsy, 2012, Sullivan et al., 
2011, Valcour et al., 2008), but hyperkinetic states like tremor which can be caused by 
disinhibition of the striatum (Oran and Bar-Gad, 2018) can be seen as well and may occur 
with or without other signs of Parkinsonism (Mirsattari et al., 1998, Cardoso, 2002, Nath 
et al., 1987). Our results demonstrate motor hyperactivity after two wks of DOX-induced 
Tat exposure (Fig 4.3 A, B) associated with reduced membrane localization of KCC2 (Fig 
4.2 C) and may serve as a mechanism underlying heightened striatal output of HIV-
induced tremor. Studies utilizing positron emission tomography to measure basal ganglia 
metabolism found that early stages of HIV-infection/HAND were associated with 
hyperactivity of the basal ganglia, followed by basal ganglia hypometabolism and 
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bradykinesia as the disease progresses (von Giesen et al., 2000). Our results with two 
wks DOX treatment may represent early disease stages, resulting in excessive striatal 
activity caused by hyperactivity in D2R-expressing MSNs of the striatum and increased 
locomotion. In fact, we have found that Tat transgenic mice also display a biphasic change 
in locomotor activity, whereby, as we have demonstrated here, hyperactivity after two wks 
of Tat exposure (Fig 4.3 A, B) and previous studies from our lab found decreased 
locomotion after four wks DOX-induced Tat expression (Hahn et al., 2016), a time point 
at which we found no differences in KCC2 (Fig 4.1), mirroring the clinical results showing 
increased then decreased striatal activation (von Giesen et al., 2000). Importantly, we 
also found that we could mitigate Tat-induced motor deficits with pharmacological 
maintenance of membrane-bound KCC2 exemplifying the utility of targeting this pathway 
as a potential therapy for PWH with motor impairment. Based on the involvement of KCC2 
in motor behavior, it is reasonable to hypothesize that KCC2 dysregulation may contribute 
to other behavioral or behavioral and cognitive deficits in Tat-transgenic mice and PWH, 
respectively, and should be explored going forward. While we found no overt changes in 
total KCC2 in the hippocampus, there may be more subtle alterations in specific neuronal 
subsets that may not be detectable by western blot of the entire hippocampus and 
changes to KCC2 localization and/or function may be present and operative in memory 
deficits seen in Tat-transgenic mice and PWH. 
Our results should be validated and expanded upon by examining the functional 
responses of D1R- and D2R-expressing MSNs by either gramicidin perforated patch 
clamp or tight-seal cell-attached current-clamp to measure Cl- reversal and GABA-
mediated postsynaptic potentials (Perkins, 2006), respectively. We hypothesize that 
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D2R-expressing MSNs would preferentially show functional deficits based on our 
colocalization results demonstrating selective vulnerability of D2R-expressing MSNs to 
Tat-induced KCC2 loss. We previously demonstrated D2R-expressing MSN vulnerability 
to Tat-induced decrease in dendritic spine density (Schier et al., 2017). Given the 
importance of KCC2 in dendritic spine stability (Fiumelli et al., 2013, Li et al., 2007), and 
our results demonstrating D2R-expressing MSN vulnerability to both KCC2 and dendritic 
spine loss, future studies should examine whether maintenance of KCC2 with CLP290 is 
sufficient to restore dendritic spines. This would further increase the therapeutic scope of 
CLP290 for utility in restoration of GABAergic function as well as excitatory circuitry. 
Interestingly, we had previously not found significant changes in locomotion in the open 
field assay after two wks DOX treatment (Schier et al., 2017). It is important to note that 
in our previous studies, we had used Tat+ and Tat- mice crossed with D1-tdTomato and 
D2-eGFP mice for all experiments reported in that paper, while the behavioral assays 
here utilized Tat+ and Tat- mice (not crossed), potentially suggesting strain differences in 
the effects of Tat on locomotion. Previous examinations of D1-tdTomato and D2-eGFP 
mice showed no difference and elevated motor activity, respectively, compared to 
C57Bl/6 control mice (Ade et al., 2011). Motor hyperactivity found in the D2-eGFP mice 
may have confounded data from the open field assay in our previous study, resulting in 
the disparate outcomes between the data presented here and those from our earlier study 
(Schier et al., 2017). Other subtle differences in experimental paradigm may explain these 
differences as well. The behavioral battery in the prior study more intensively explored 
anxiety-like behaviors measured with the elevated plus maze on the same day as the 
open field assay and differences in assay length: 20 min versus 30 min for the present 
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study and previous examinations, respectively. Whether these or other potential 
confounds (such as experimenter or prior handling) produced the discrepancies between 
these studies should be examined going forward. 
HIV infection has many comorbidities including substance use disorder (SUD) and 
drug use can affect the progression of HAND (NIDA, 2019, Canan et al., 2018, Denis et 
al., 2019, Bell et al., 2002, Byrd et al., 2011). PWH have also been shown to have 
disrupted reward processing, placing them at higher risk for adverse outcomes associated 
with SUD (Anderson et al., 2016, Plessis et al., 2015). Drugs of abuse have profound 
impact on striatal circuitry and can result in long term circuit changes resulting in 
dependency (Koob and Volkow, 2010). Our previous work demonstrated that activation 
of µ-opioid receptor by morphine can reduce KCC2 in human neurons in vitro (Chapter 
3) and previous studies have shown that opiate dependency can induce a GABA switch 
from inhibitory to excitatory (Laviolette et al., 2004, Vargas-Perez et al., 2009). While not 
directly explored, changes in KCC2 activity may underlie this shift. Fitting et al. (2010) 
also demonstrated that opiate exposure can exacerbate Tat-induced striatal dendritic 
pathology (Fitting et al., 2010). Given striatal vulnerability to disruption from both HIV and 
drugs of abuse, the experiments performed here should be expanded to examine how 
drugs of abuse may interact with Tat to affect striatal KCC2, GABAergic function, and 
associated behavioral outputs. Further, Tat exposure has increased cocaine induced 
motor hyperactivity (Harrod et al., 2008, Paris et al., 2014a). Thus, these factors may 
converge to dysregulate KCC2, exacerbating motor hyperactivity.  
CLP290 administration had previously been utilized to restore KCC2 Cl- extrusion 
and walking in spinal cord injured mice (Chen et al., 2018), morphine-induced 
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hyperalgesia in rats (Ferrini et al., 2017), and somatosensory-related behavior after 
traumatic brain injury (Lizhnyak et al., 2019). Here, we increased membrane-localized 
KCC2 and restored motor activity to baseline levels after two wks of CNS exposure to 
Tat. Membrane-localization and degradation of KCC2 is tightly regulated by several 
different phosphorylation events. While its efficacy has been well documented, the 
mechanism by which CLP290 reestablishes KCC2 activity remains elusive. Our results 
suggest that CLP290 rescues KCC2 activity by restoring phosphorylation of S940 to 
increase membrane stabilization of KCC2 and, therefore, Cl- extrusion. Whether CLP290 
directly interacts with KCC2 to maintain S940 phosphorylation, or if it enhances PKC or 
inhibits PP1 to increase or decrease S940 phosphorylation, respectively, is unknown and 
should be explored in future studies. 
These experiments demonstrate the role of KCC2 in behavioral deficits induced by 
CNS exposure to Tat which add to our previous in vitro studies in which we first identified 
dysregulation of KCC2 by HIV-1 and the Tat and gp120ADA HIV proteins. KCC2 is 
emerging as a key regulator of hyperexcitability in several neurological disorders and the 
use of CLP290 has shown promise for pharmacological reintroduction of KCC2 and 
rescue of physiological and behavioral deficits. We provided evidence that begins to 
uncover the mechanism by which CLP290 reinstates KCC2 activity which had previously 
not been described. Overall, we add in vivo biochemical and behavioral evidence to the 
utility of targeting KCC2, perhaps with CLP290, as a potential therapy for PWH with 






Figure 4.1. Two wk DOX-induced Tat expression in Tat+ mice reduced total 
striatal KCC2. Analysis of western blot from hippocampus animals administered DOX 
for two (p = 0.82, n = 6), four (p = 0.51, n = 6), and eight wks (p = 0.65, n = 7) show 
no significant differences between Tat+ and Tat- mice (A). Two wk DOX administration 
significantly reduced total KCC2 in the striatum of Tat+ mice compared to Tat- mice 
(** p = 0.001, n = 11 – 12) and four wk DOX groups showed no significant differences 
(p = 0.28, n = 6). Representative blots showing decreased KCC2 in Tat+ mice 
compared to Tat- after two wk DOX treatment (B; right). All KCC2 western blots are 





















Figure 4.2. CLP290 administration rescues phosphorylation of S940 and 
membrane localization of KCC2. Two-way analysis revealed a main effect of Tat 
expression to reduce total KCC2 (**, p < 0.01, n = 12 – 18) suggesting that CLP290 
failed to rescue total KCC2 levels (A). Examination of phosphorylation of S940 
revealed a significant decrease in the Tat+/Vehicle group compared to control (** p < 
0.01, n = 8 – 12) and rescue with CLP290 (* p < 0.05, n = 8 – 12) (B) suggesting that 
membrane bound KCC2 may be altered, which was confirmed by western blot on from 
membrane fractionation (** p < 0.01; *p < 0.05, n = 8 – 9) (C). Blots for total and pS940-
KCC2 are represented as intensity relative to GAPDH normalized to Tat-/Vehicle 
controls (A, B). Blots for membrane bound KCC2 are relative to total lane protein 





















Figure 4.3. Tat+ mice show hyperactive locomotion in the open field assay with 
CLP290 able to rescue this effect.  Tat+ mice given vehicle showed increased motor 
activity compared to controls in the open field assay measured by both total distance 
travelled (A) and rearing number (B) (**, p < 0.01, n = 8 – 9). CLP290 administration 
significantly decreased total distance travelled and rearing number in Tat+ mice (*, p 
> 0.05, n = 8 – 9), suggesting that restoration of membrane-localized KCC2 was 
sufficient to rescue abnormal locomotor activity in these animals. We also examined 
time spent in center zone as a measure of anxiety-like behavior and found no 



























Figure 4.4. D2R-expressing MSNs display Tat-induced KCC2 loss while D1R-
expressing MSNs do not. Colocalization analyses revealed no change in KCC2 
immunofluorescence with tdTomato between Tat+ x Drd1a-tdTomato and Tat- x 
Drd1a-tdTomato mice (n = 3 (Tat-), 12 (Tat+)) (A, B). Representative images showed 
no change in KCC2 immunofluorescence in D1R-expressing MSNs (tdTomato). 
Yellow arrows exemplify somatic KCC2 staining, localized around the cell membrane, 
in D1R-expressing MSNs (A). Tat+ x Drd2-eGFP mice showed decreased 
colocalization with KCC2 immunofluorescence compared to Tat- x Drd2-eGFP mice 
(*p < 0.05; n = 8) (C, D). Representative images showed strong colocalization in D2R-
expressing MSNs of Tat- mice, while Tat+ mice showed decreased 
immunofluorescence colocalized with D2R-expressing MSNs (eGFP) (C). Yellow 
arrows exemplify somatic membrane KCC2 colocalization with D2R-expressing MSNs 
(top C). White arrows exemplify D2R-expressing neurons with reduced KCC2 cell 
membrane localization and decreased colocalization with eGFP (bottom C). These 
results suggest a preferential vulnerability of D2R-expressing MSNs to Tat-induced 




Conclusions and Future Directions 
 
 The introduction of cART has changed the prognosis of an HIV-1 infection from a 
virtual death sentence to a manageable chronic condition. Thus, the focus of treatments 
for these patients has shifted from prophylaxis against opportunistic infection to viral 
suppression and improvement of quality of life. Even with cART adherence, HAND is a 
preeminent complication for up to 50% of PWH (Heaton et al., 2010). Neuronal 
hyperexcitability along with reduced synaptodendritic complexity underlies disrupted 
circuitry that manifests as cognitive and behavioral alterations associated with HAND 
(Masliah et al., 1997). Heightened glutamatergic signaling plays a significant role and has 
classically been the center of focus when studying hyperexcitability. Mounting evidence 
also demonstrates disrupted GABAergic signaling as a vital component to this process 
(Gelman et al., 2012a, Buzhdygan et al., 2016). The evidence presented in this 
dissertation demonstrates that KCC2 plays an integral role in disrupting the postsynaptic 
response in GABAergic signaling, contributing to hyperexcitability of the HIV-exposed 
CNS. Through experiments involving a novel human in vitro model and DOX-inducible, 
GFAP-driven Tat-transgenic mice we determined that HIV-1, and viral proteins diminish 
KCC2 resulting in GABAAR signaling deficits and behavioral abnormalities. Most of these 
deficits were ameliorated pharmacologically using the KCC2 enhancer, CLP257, and its 




 SUD is a common comorbidity of HIV-infection. IDU was responsible for ~20% of 
new HIV-1 cases in 2016 and up to 50% of PWH are prescribed opiates (NIDA, 2019, 
Denis et al., 2019, Chilunda et al., 2019). Regardless of whether use is illicit or prescribed, 
opiate exposure results in faster progression of AIDS (Peterson et al., 1990, Peterson et 
al., 2004), and possibly, exacerbated HAND symptomology (Bell et al., 2002, Bell et al., 
1998, Byrd et al., 2011, Chiesi et al., 1996, Lucas et al., 2006). These enhanced 
symptoms are likely the result of cellular signaling convergence from HIV proteins and 
opiate activation of MOR in areas of the brain vulnerable to insult from both factors, such 
as the hippocampus and striatum. Previously identified targets of morphine-HIV neuronal 
signaling convergence include GSK3β (Masvekar et al., 2015), and p38 mitogen activated 
protein kinases (MAPK) (Mukerjee et al., 2008, Hu et al., 2005) which can enhance 
neuronal death in vitro. Our results demonstrate that morphine activation of MOR can 
independently reduce KCC2 and disrupt GABAAR-mediated hyperpolarization and 
inhibition and has a significant or trend toward a combinatorial effect with HIV-Tat and 
gp120, respectively, to enhance KCC2 loss under certain conditions (Chapter 3; Fig 3.1, 
3.2, 3.4, 3.5, 3.6). Thus, our in vitro results provide a cellular/molecular substrate upon 
which opiates disrupt GABA signaling and can converge with HIV protein-mediated 
pathways to enhance these effects. 
Opiate administration activates MOR on GABAergic interneurons of the VTA, 
inhibiting GABA release from this neuronal subpopulation, thus, disinhibiting DAergic 
neurons, increasing DA release on the NAcc inducing feelings of euphoria and promoting 
opiate dependence. Previous studies have demonstrated that opiate dependence and 
withdrawal cause a switch of GABA on VTA GABAergic terminals from inhibitory to 
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excitatory, although they did not provide a mechanistic cause of this physiological reversal 
(Laviolette et al., 2004, Vargas-Perez et al., 2009). Our results provide the first direct link 
between MOR activation and diminished KCC2 and neuronal disinhibition (Chapter 3; Fig 
3.1, 3.6). Thus, it is feasible that MOR activation after repeated exposures to opiates in 
vivo results in decreased KCC2 on GABAergic interneurons of the VTA. This, in turn, 
necessitates continual MOR activation to maintain their inhibition (through neuronal Gi/o 
signaling) thereby maintaining VTA DAergic activity, which would promote opiate 
dependency. Removal of MOR activation disinhibits these GABAergic interneurons, 
which is now exacerbated by reduced KCC2 and GABAAR-mediated excitation and thus, 
strongly inhibits VTA DAergic neuronal activity on the NAcc inducing a withdrawal state. 
This proposed mechanism of KCC2-driven opiate dependency and withdrawal should be 
investigated in vivo to determine if opiate dependency and withdrawal reduce KCC2 in 
GABAergic interneurons of the VTA and if modulation (perhaps with CLP290) affects 
outcomes associated with excitatory GABA and opiate dependency and withdrawal. 
Signaling from HIV and drugs of abuse converge on the striatum and studying their 
interactive effects may give insight to the vulnerability of PWH to reward deficits. These 
deficits have been reflected in studies in which Tat+ mice showed a three-fold increase 
in both ethanol and cocaine conditioned place preference (CPP) compared to controls 
(Paris et al., 2014a, McLaughlin et al., 2014). These behavioral changes are 
accompanied by significant changes in DAergic markers (Kesby et al., 2016, Ferris et al., 
2009a, Ferris et al., 2009b) and drug of abuse enhancement of striatal MSN damage 
(Fitting et al., 2010, Bruce-Keller et al., 2008). Classic theories on reward circuitry, 
typically studied in regard to drugs of abuse, proposed a diametrically opposed role of 
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D1R and D2R-expressing MSNs. D1R-expressing MSNs theoretically encode reward and 
are activated by drugs of abuse and whose stimulation can induce/potentiate CPP, 
whereas D2R-MSNs encode aversion and inhibit drugs of abuse-induced CPP (Lobo et 
al., 2010, Hikida et al., 2010, Tai et al., 2012, Kravitz et al., 2012). This controversial 
theory of reward circuitry has come into question in more recent studies (Soares-Cunha 
et al., 2016, Natsubori et al., 2017, Cole et al., 2018) exemplified by a 2019 publication 
that demonstrated that both D1R and D2R-expressing MSNs can encode reward, 
dependent on neuronal stimulation frequency, determined by selective optogenetic 
activation of D1R and D2R-expressing MSNs (Soares-Cunha et al., 2019). Our data 
suggests GABAergic disruption in the striatum of Tat+ mice, specifically, disinhibition of 
D2R-expressing MSNs is mediated through reduced KCC2 (Chapter 4, Fig 4.3, 4.4). 
These may be involved in the sequelae of events resulting in Tat-potentiated cocaine and 
ethanol reward salience and reward deficits in PWH. Future studies should examine if 
modulation/restoration of GABAergic inhibition of D2R-expressing MSN could ameliorate 
Tat-potentiated CPP. 
It is important to note the hNeuron in vitro model described in Chapter 2 and utilized 
in Chapter 3 is a mixed neuron-glia (astrocyte) co-culture. Thus, it may be direct neuronal 
MOR activation or activation of MOR on glia, which through an unknown mediator, acts 
on neurons to diminish KCC2. Ferrini et al (Ferrini et al., 2013) demonstrated that 
morphine-induced KCC2 reductions in the spinal cord induce hyperalgesia and were 
mediated by microglial purinergic receptor activation. Additionally, previous studies in our 
lab have rarely found interactions between HIV proteins and opiates in vitro with less than 
24 h exposures and combinatorial effects from these factors at later time points are 
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consistently mediated by glia (Zou et al., 2011, Kim et al., 2018). When taken together 
with our results showing morphine-Tat interactions at 24 h, but not at 6 h, it may be that 
morphine-induced KCC2 loss is glial-mediated (Fig 5.1). 
 The role of KCC2 dysregulation has been investigated in several neurological 
disorders (outlined in Chapter 1) and we are the first to demonstrate its role in neuroHIV 
(Chapters 3, 4). While these neurodegenerative disorders have different etiologies, there 
are several common hallmarks between them such as neuroinflammation and elevated 
glutamatergic signaling. Another emerging commonality is neuronal Cl- gradient collapse 
via reduced KCC2 activity, resulting in neuronal disinhibition through diminished 
GABAAR- mediated hyperpolarization and inhibition, and in some cases, GABAAR-
mediated depolarization and excitation. While there are common pathways, the cognitive 
and behavioral consequences are often vast. These differences arise in age of onset, 
brain regions and neuronal subsets affected, white matter involvement, and differences 
in immune recruitment, among others. For example, Rett Syndrome has large-scale 
behavioral and cognitive abnormalities compared to those typically seen with HAND. 
These differences arise in their separate etiologies: Rett is a genetic disorder and, thus, 
these KCC2 deficits result in improper GABAergic tuning during a critical period of CNS 
development (as well as other cellular and molecular sequelae differences), resulting in 
large-scale cognitive deficits. HIV is typically acquired after these critical periods of 
development, and, thus, the deficits of HAND are comparatively, subtle. Loss of KCC2 
function has a well-established link to epilepsy via neuronal disinhibition, but seizures are 
not always seen in states of lowered KCC2 and while the rates of epilepsy due to HIV 
infection (~4%) are higher than the general population (1.2%), they are still low 
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(Kellinghaus et al., 2008). The involvement of KCC2 in epileptogenesis is likely due to 
extent of KCC2 activity loss and brain regions and neuronal subsets affected. Extreme 
loss of KCC2 activity may result in accumulation of [Cl-]i to the point of Cl- efflux upon 
GABAAR activation resulting in depolarization, and possibly neuronal excitation. The 
subsets of neurons affected have drastic effects on neuronal micro- and macro-circuitry. 
For example, ablation of KCC2 in pyramidal neurons of the hippocampus resulted in 
GABAAR-mediated depolarization and was sufficient to induce temporal lobe epilepsy 
(Kelley et al., 2018). In contrast, our results suggest that HIVsup ± morphine-induced KCC2 
activity loss are not as profound, as there is still hyperpolarization due to GABAAR 
activation (Fig 3.2). Our in vivo data showed KCC2 loss in D2R-expressing MSNs of the 
striatum, but we found no overt loss of KCC2 in the hippocampus (Fig. 4.1, 4.4) and while 
Tat+ mice have displayed lower kainite-evoked seizure thresholds (Zucchini et al., 2013), 
epilepsy has not been noted in Tat-transgenic mice. Thus, HIV exposure may be 
associated with KCC2 loss and hyperexcitability, but the development of epilepsy 
depends on differences in extent of [Cl-]i accumulation and neuronal subsets and brain 
regions with reduced KCC2 activity. Despite differing etiologies, neuronal subpopulation 
and brain region involvement, and cognitive/behavioral consequences, the commonalities 
underlying the neuropathology of these disorders suggest that there may be common 
therapies between them. 
 CLP257 and its prodrug, CLP290, are capable of maintaining membrane 
expression of KCC2, and thus maintain neuronal Cl- extrusion, but the mechanism 
underlying these effects has yet to be elucidated. We demonstrated its utility in vitro in 
maintaining KCC2 immunoreactivity and GABAAR-mediated hyperpolarization and 
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inhibition after exposure to HIVsup, Tat, and morphine exposure (Chapter 3, Fig 3.1, 3.2, 
3.4, 3.5, 3.6). In vivo studies found that CLP290 could restore KCC2 and GABAergic 
activity to reactivate neuronal circuitry after spinal cord injury reinstating walking (Chen et 
al., 2018), restore somatosensation after TBI (Lizhnyak et al., 2019), and reverse 
morphine induced hyperalgesia (Ferrini et al., 2017). We found that daily oral gavage of 
CLP290 for seven days during the second week of DOX treatment was capable of 
ameliorating abnormal motor activity in Tat+ mice (Chapter 4, Fig 4.4). While unable to 
rescue total KCC2 levels, CLP290 administration did rescue pS940-KCC2, and 
membrane localized KCC2, suggesting rescued neuronal Cl- gradient and proper 
GABAergic transmission (Chapter 4, Fig 4.3). These results also provide insight to a 
possible mechanism that CLP290 acts. Our results demonstrate that CLP290 rescues 
membrane localization of KCC2 through maintenance of pS940. Although whether 
CLP290 interacts directly with KCC2 to prevent PP1 dephosphorylation of KCC2, inhibits 
PP1 itself, enhances PKC phosphorylation of S940, or modulates activity upstream of 
PP1 or PKC is unknown. It is also possible that CLP290 maintains other phosphorylation 
states important for membrane localization/degradation and these phosphorylation 
specific residues should be examined going forward. Our results demonstrated a failure 
of CLP257 to restore KCC2 and GABAAR-mediated inhibition after exposure to gp120ADA 
(Chapter 3, Fig 3.5, 3.6). Taken together with our data implicating involvement of pS940 
in CLP290s mechanism of action, suggests that gp120ADA may dysregulate pathways 
involved in the mechanism of action of CLP290.  
The primary therapy for HAND is viral suppression via cART. Since its introduction, 
there has been a reduction of the most severe form of HAND, HAD, but there has been 
103 
 
an increase in the two milder forms with an overall prevalence remaining the same 
(Heaton et al., 2010). While able to control viral loads in the periphery, the CNS can act 
as a reservoir for HIV which may play a role in the persistence of HAND. Other factors 
that may be implicated in continuing neurocognitive detriment include an aging HIV 
population and, potentially, neurotoxic effects from some ARVs. Regardless of the cause, 
this preeminent quality of life issue for PWH underscores the necessity for adjuvant 
therapies to ameliorate the symptoms of HAND. As the preeminent theories for neuronal 
dysfunction in HAND centered around glutamatergic and Ca2+ signaling, so did trials for 
adjuvant therapies. Trials for NMDAR antagonist, memantine, and voltage gated L-Type 
Ca2+ channel, nimodipine had little to no success at restoring or decelerating deficits of 
HAND (Schifitto et al., 2007, Navia et al., 1998). Other adjuvant therapies to reach clinical 
trial have been a monoamine oxidase B inhibitor, selegiline, (Sacktor et al., 2009), TNF 
antagonist, CPI-1189 (Clifford et al., 2002) an acetylcholinesterase inhibitor, rivastigmine 
(Sacktor et al., 2011), and valproic acid (Schifitto et al., 2006), none of which significantly 
improved symptoms of HAND. Going forward, targeting KCC2, perhaps with CLP290 may 
prove to be beneficial to restore GABAergic inhibition and ameliorate the excitatory-
inhibitory imbalance of the HIV-exposed CNS as discussed thoroughly in chapters 3, 4, 
and 5. At this time, CLP290 has not been tested in clinical trials. Bumetanide, a diuretic 
that is approved for clinical use, has been shown to restore neuronal Cl- gradient via 
antagonism of NKCC1. Acting in opposition to KCC2, NKCC1 increases neuronal [Cl-]i, is 
the dominant neuronal Cl- transporter in the immature brain and is aberrantly increased 
in some neurological disorders. Clinically, bumetanide significantly reduced seizure 
frequency in temporal lobe epilepsy (Eftekhari et al., 2013) and benefited neurocognitive 
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and behavioral outcomes for those suffering from drug-resistant epilepsy (Gharaylou et 
al., 2019), autism (Lemonnier and Ben-Ari, 2010, Lemonnier et al., 2012, Lemonnier et 
al., 2017), and schizophrenia (Lemonnier et al., 2016) through restoration of inhibitory 
GABAergic signaling. While we saw no changes in NKCC1 in our in vitro experiments, 
future studies should examine NKCC1 changes in Tat transgenic mice and human tissue 
to determine if this could be a potential adjuvant therapy for PWH experiencing 
neurocognitive decline. 
Our discovery that CCR5 mediates KCC2 immunoreactivity and inhibitory effects 
of GABA (Chapter 3; Fig 3.5, 3.6) is a novel mechanism of neuro-immune interaction and 
may have implications for PWH as well as other neuroinflammatory disorders. MVC, an 
FDA approved CCR5 antagonist, is a commonly prescribed ARV to prevent viral entry 
with high CNS penetrance (Yilmaz et al., 2009). A clinical study found that when MVC 
use was intensified, PWH with neurocognitive impairment had significant improvements 
in global functioning, learning and memory, and executive function (Ndhlovu et al., 2014). 
Thus, restored KCC2 and GABAergic hyperpolarization may be a molecular and 
physiological mechanism underlying improvements in these subjects. To our knowledge, 
this is the first time a chemokine receptor has been linked to changes in KCC2. This route 
of neuro-immune crosstalk demonstrates a novel pathway by which immune activation 
can fine-tune neuronal circuitry and induce hyperexcitability and, therefore, may be 
involved in other disorders that show operative CCR5-CCL5 signaling. For example, 
multiple sclerosis increases CCL5 (Sorensen et al., 1999). Of particular relevance, one 
study with multiple sclerosis patients used a paired pulse transcranial magnetic 
stimulation (TMS) protocol to induce intracortical inhibition (inter stimulus interval of 2 
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ms), which is GABAAR mediated (Di Lazzaro et al., 2006), and found decreased paired 
pulse-induced cortical inhibition was significantly correlated with subjects CSF CCL5 
levels (Mori et al., 2016). Thus, these results may be explained by decreased GABAAR 
inhibition via increased CCR5 activation and subsequent reduction in KCC2 activity. 
Given this novel CCR5-KCC2 signaling cascade, MVC should be considered more 
heavily for PWH experiencing neurocognitive decline and should be examined for use in 
other disorders in which elevated CCL5-CCR5 signaling is a component of 
neuroinflammation. 
 D2R-expressing MSNs seem to be particularly vulnerable to hyperexcitability 
(Cepeda et al., 2008) and excitotoxicity through glutamate receptor activation (Mesco et 
al., 1992). Previous studies from our lab have demonstrated vulnerability of striatal 
neurons, particularly D2R-expressing MSNs, of Tat+ mice to dendritic spine loss induced 
by elevated [Ca2+]i (Fitting et al., 2014, Fitting et al., 2010, Schier et al., 2017). KCC2 
interactions with cytoskeletal elements to maintain dendritic spines and our results 
showing Tat-induced, NMDAR-dependent KCC2 loss (Fig 3.1, 3.4), suggest that the Tat-
induced neuropathology (dendritic spine and KCC2 loss) noted between these studies 
may be part of the same signaling cascade. We propose that Tat-mediated NMDAR-
dependent [Ca2+]i elevation induces dephosphorylation of S940 and KCC2 internalization 
and degradation, preferentially in D2R-expressing MSNs, destabilizing and ultimately 
reducing dendritic spine density. Thus, Tat induction induces striatal inhibitory and 
excitatory dysfunction through KCC2 reduction and subsequent dendritic spine loss, 
respectively. These interactions should be examined by determining if KCC2 
maintenance (with CLP290) is sufficient to restore dendritic spines on D2R-expressing 
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MSNs which may also broaden the therapeutic potential of targeting KCC2 with drugs like 
CLP290. 
While motor disorders associated with HAND typically involve hypokinetic states, 
such as bradykinesia, our results demonstrate hyper locomotion in the open field assay 
after two wks DOX treatment. These seemingly paradoxical results may actually reflect 
the biphasic nature of striatal activation and motor impairment seen in PWH (von Giesen 
et al., 2000). Early in disease progression, subjects showed hypermetabolism of the 
striatum measured by positron emission tomography, while in more advanced stages of 
HIV infection subjects showed striatal hypometabolism and motor slowing. When taken 
together, the behavioral results presented in this dissertation showing increased motor 
activity after two wks of DOX-induced Tat expression (Fig 4.3) and previous work form 
our lab demonstrating decreased locomotion after 4 wk DOX treatment, reflect the 
progression of motor changes in PWH. Further, these locomotor changes also follow the 
biphasic response of KCC2 loss examined in Chapter 4 (Fig 4.1, 4.2). In accordance with 
decreased KCC2 in D2R-expressing MSNs (and, therefore, likely disinhibition of these 
cells), there is an increase in motor activity and as we see a recovery of KCC2 to baseline 
levels at four wk DOX-induced Tat exposure, there is a reversal in motor effects to 
hypolocomotion in the open field assay (Hahn et al., 2016). These results stand in 
contradiction to the classic ‘Go/ No Go’ theory of striatal motor activation and support 
emerging evidence showing that either D1R- or D2R-expressing MSN activation are 
implicated in motor initiation which is covered in the discussion of Chapter 4. Overall, we 
propose that the increased striatal output seen early in disease progression in PWH may 
be a result of decreased striatal KCC2 (preferentially in D2R-expressing MSNs), resulting 
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in neuronal disinhibition, thus increasing striatal activity, and as KCC2 returns to baseline, 
giving way to more prolonged circuit changes and DA depletion, there is a reversal of 
striatal activity manifesting as hypokinesia, resulting in the striatal hypometabolism and 
Parkinsonian-like states described clinically. 
 
Final Conclusion 
The work performed for this dissertation described two in vitro models with 
particular utility for HAND, one of which we used to identify a novel target of HIV and 
opiates to disrupt GABAergic signaling. Pharmacological manipulation of this novel target, 
KCC2, with CLP257 restored GABAAR-mediated hyperpolarization and inhibition. In vitro 
experiments performed in Chapter 3 have implications beyond the neuroHIV and drug 
abuse fields. We identified CCR5-KCC2 as a novel intermediary of neuro-immune 
interaction by which chemokine receptor signaling can disrupt GABAAR activity. 
Additionally, these studies demonstrated that morphine activation of MOR decreases 
KCC2, and may provide insight to the molecular substrate implicated in the synchrony of 
events resulting in GABAergic reversals in opiate-dependent animals. We expanded our 
in vitro KCC2 results to the Tat-transgenic mouse and found reduced striatal KCC2 after 
two wks of Tat expression. Additionally, D2R-expressing MSNs of the striatum seem to 
be preferentially vulnerable to KCC2 loss and these changes were associated with hyper 
locomotion. We were able to restore basal motor activity and membrane localized KCC2 
through rescue of phosphorylation of S940-KCC2 with CLP290 oral gavage, providing 
insight to a potential mechanism by which this drug works. In total, the studies presented 
describe a promising therapeutic target for HAND and implicate a common mechanism 
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between HIV proteins and morphine to dysregulate GABAergic activity, which may have 
























Figure 5.1. Mechanisms underlying Tat, gp120ADA, and morphine-induced KCC2 
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